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RÉSUMÉ 
Interaction entre les voies de signalisation TAF6δ et Notch dans des lignées de cellules 
Cancéreuses  
Par 
Edith Milena Alvarado Cuevas 
Programme de microbiologie et d´infectiologie 
 
Mémoire présenté à la Faculté de médecine et des sciences de la santé en vue de l’obtention 
du diplôme de maître ès sciences (M.Sc.) en microbiologie et d´infectiologie, Faculté de 
médecine et des sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec, 
Canada, J1H 5N4 
La voie de signalisation de Notch contrôle de multiples processus cellulaires, telle la 
différenciation, la prolifération cellulaire et l’apoptose. Son activation repose sur la liaison 
du récepteur Notch par son ligand. Par la suite, le domaine intracellulaire actif de Notch 
(NIC) est relâché après son clivage médié par la γ-sécrétase. Cela permet au NIC d’être 
transporté au noyau où celui-ci lie la protéine CSL et active la transcription de ses gènes 
cibles, comme Hes1. TAF6 est une sous-unité du facteur de transcription général TFIID qui 
joue un rôle important dans la régulation de la transcription effectuée par l’ARN polymérase 
II. L’isoforme TAF6δ peut induire l’apoptose et aussi l’expression des gènes cibles de Notch.  
Cette étude a pour objectif d’explorer l’interaction croisée entre les voies de signalisation de 
Notch et de TAF6δ et leur impact sur l’apoptose. Pour valider l’impact de l’expression de 
TAF6δ sur la voie de signalisation de Notch, nous avons effectué une analyse par micropuce. 
L’expression de TAF6δ médiée par la transfection de SSOs (oligonucléotides Splice-
Switching) a révélé une induction γ-sécrétase dépendante de gènes cibles de Notch dans les 
cellules HeLa. La cytométrie de flux a en outre montré que l'apoptose TAF6δ-dépendante est 
réduite par un traitement avec des inhibiteurs de gamma-sécrétase. L'analyse par 
immunofluorescence a révélé que TAF6δ induit la translocation de NIC-2 au noyau. Enfin, 
une analyse par qPCR a montré que l'expression du gène cible Notch est augmentée dans 
plusieurs lignées de cellules cancéreuses en réponse à l’induction TAF6δ. Nos données 
montrent, que la voie de signalisation de Notch est activée par TAF6δ dans plusieurs modèles 
de cancer et que l’interaction entre ces deux voies contribue à l'apoptose dans un modèle de 
cancer du col de l'utérus.  
 
Mots-clés : TAF6δ ; voie Notch ; l'activation transcriptionnelle ; cancer du col utérin. 
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SUMMARY 
 Crosstalk between TAF6δ and Notch Signalling Pathways in Cancer Cell Lines 
 
By 
Edith Milena Alvarado Cuevas 
 Department of Microbiology and infectiology 
 
Thesis presented at the Faculty of medicine and health sciences to obtain the Master degree 
diploma of Sciences (M.Sc.) in Microbiology and infectiology, Faculty of medicine and 
health sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
 
Background: The Notch pathway controls multiple cellular processes, such as 
differentiation, cell proliferation and apoptosis. Its activation is based on the ligand binding 
to a Notch receptor after which, the Notch intracellular active domain (NIC) is released 
through cleavage mediated by γ-secretase. Upon cleavage, NIC translocates to the nucleus, 
where it binds CSL (CBF1/Su (H)/Lag-1) and activates the transcription of its target genes 
such as Hes1. TAF6 is a subunit of the TFIID basal transcription complex that plays an 
important role in the regulation of RNA polymerase II transcription. TAF6δ is a specialized 
isoform of TAF6 that can induce apoptosis and induces the expression of Notch target genes. 
This study aims to explore the potential crosstalk between TAF6δ and Notch signalling 
pathways and its impact on apoptosis. 
Results: To validate the impact of TAF6δ expression on the Notch pathway, we performed 
microarray analysis. TAF6δ induction, mediated through transfection of SSOs (Splice-
Switching oligonucleotides), revealed a γ-secretase–dependent induction of Notch target 
genes in HeLa cells. Flow cytometry analysis further showed that TAF6δ-dependent 
apoptosis is reduced by treatment with γ-secretase inhibitors. Immunofluorescence analysis 
revealed that TAF6δ induced translocation of NIC-2 to the nucleus. Finally, qPCR showed 
that Notch target gene expression is increased in several cancer cell lines in response to 
TAF6δ induction.  
Conclusion: Our data show that the Notch pathway is activated by TAF6δ in several models 
of cancer, and that this association contributes to apoptosis in cervical cancer.  
 
Keywords: TAF6δ; Notch pathway; Transcriptional activation; cervical cancer. 
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1.1 PROGRAMMED CELL DEATH 
 
 The term “Programmed” was defined as the “exact instance in which 
physiological cell death occurs” (Bruce Alberts 2002). Programmed cell death 
(PCD) is important in different biological phenomena such as ageing, 
development and pathology. Therefore, in multicellular organisms the number of 
cells is highly regulated by controlling not only the proportion of proliferation but 
also the proportion of cell death, such as the loss of cells during aging and 
development, thus establishing a balance (Lockshin and Beaulaton 1974, Bruce 
Alberts 2002). Since PCD was originally discovered, several studies reported 
different mechanisms of cell death. Specifically, three types of cell death have 
been classified:  
 
 Type I: Apoptosis, a physiological process that kill useless cells during 
development, but does not generate an inflammatory reaction because the cells 
do not release the cellular components within the surrounding tissue, are 
phagocytosed quickly and do not produce anti-inflammatory cytokines (Rode 
2005, Elmore 2007). 
 
 Type II: Autophagy, a catabolic process that responds to extracellular or 
intracellular stress and sequestrates cytosolic structures, organelles and 
aggregates of proteins in a membrane vesicle called the autophagosome. 
Autophagosomes are degraded by lysosomes (Coates et al. 2010, Ouyang et al. 
2012, Fuchs and Steller 2015). 
 
 
 Type III: Necrosis, a pathological process that is distinguished by the swelling of 
cells and organelles, which lead to damage of the plasma membrane and release 
of intracellular contents. Due to the rupture of the cells and the release of their 
contents, necrosis results in an intense inflammatory response (Choudhury et al. 
2012, Fuchs and Steller 2015). 
 
 
3 
3 
1.2 APOPTOSIS 
 
1.2.1 Definition 
 
The term apoptosis was first introduced by Kerr, Wyllie and Currie (Kerr et al. 1972) and is 
derived from the Greek language “απόπτωσις”, meaning leaves falling off trees or petals 
dropping off flowers (Hongmei 2012). Apoptosis represents a normal physiological 
mechanism that allows the removal of damaged or excessive cells to balance cell division 
with cell death during development. Apoptosis, also known as physiological cell death, cell 
suicide, cell deletion and programmed cell death (PCD) plays an important role during the 
physiological processes of multicellular organisms, especially during embryogenesis and 
metamorphosis (Gewies 2003, Choudhury et al. 2012). One of the main functions of PCD is 
to maintain a balance in the development and maintenance of multicellular biological systems 
that depends on sophisticated interconnections between the cells that form the organism. 
Apoptosis is also tightly regulated during development when many cells are overproduced 
and subsequently undergo PCD. Developmental processes require a balance between the 
number of cells generated by proliferation and the number of cells that are killed by cell 
death, contributing to the tissue-specific regulatory mechanisms underlying the formation of 
many organs (Zhang and Herman 2002, Gewies 2003, Dlamini et al. 2004). A relevant 
example is the role played by apoptosis in the regulation of the immune system. Lymphocytes 
T matured in the thymus are responsible for destroying infected cells in the body but before 
they enter the bloodstream, they have to be tested to validate their reactivity against foreign 
antigens, but not self-antigens. Therefore, some inefficient and self-reactive lymphocytes T 
are subjected to cell death controls at many points during their lifespan to maintain peripheral 
homeostasis and prevent autoimmunity (Figure 1) (Rathmell and Thompson 2002, Dash 
2015). 
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Figure 1. Apoptotic morphological changes. T-cells undergoing apoptosis in 
vitro and in the thymus after activation. Morphological appearance of the dying 
cell observed by electron micrographs. (A) Corresponding to a blebbing cell and 
(B) corresponding to nuclear condensation. (From Zimmermann, Bonzon et al. 
2001).  
 
The aberrant regulation of apoptosis is implicated in the emergence of numerous diseases, 
including neurodegenerative disorders (Alzheimer, Huntington and Parkinson), 
cardiovascular diseases (Myocardial, Stroke) and hematologic diseases (Aplasia anaemia), 
where there is excessive apoptosis. In contrast, insufficient apoptosis, outpaced by 
proliferation, can lead to cancer, restenosis, and autoimmunity (Kiechle and Zhang 2002, 
Reed 2002, Rajesh P. Rastogi 2009, Coates et al. 2010).   
 
1.2.2 Morphologies of apoptosis 
 
Apoptosis can be induced by several stimuli from outside or within the cell, such as strong 
DNA damage, chemical drugs or irradiation, as well as lack of survival pathways or increased 
death signals (Gewies 2003). The morphological hallmarks of the dying cell have been 
identified by light and electron microscopy, which includes membrane blebbing, chromatin 
condensation, nuclear DNA fragmentation, cell rounding concomitant with loss of adhesion 
to neighbouring cells, and cell shrinkage (Fuchs and Steller 2015). Morphological changes 
in cell shrinkage are visible by light microscopy, such as small size, tightly packed organelles 
and condensed cytoplasm. Electron microscopy has also been used to detect subcellular 
changes at higher resolution (Elmore 2007). Cell fragments are compacted into membrane-
(A) (B) 
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bound apoptotic bodies containing organelles, cytosol and condensed chromatin that are 
rapidly phagocytosed by macrophages and neighbouring cells such as neoplastic and 
parenchymal cells. Ultimately, apoptotic bodies are degraded in phagolysosomes of 
phagocytic cells (Van Cruchten and Van Den Broeck 2002, Elmore 2007). All the 
morphological changes in apoptotic cells are caused by a number of molecular and 
biochemical events that includes the involvement of proteolytic enzymes that permit the 
cleavage of DNA into oligonucleosomal fragments and the cleavage of a multitude of 
protein-specific substrates, which often establish the integrity and shape of the cytoplasm or 
organelles (Saraste and Pulkki 2000). 
 
1.2.3 Mechanisms of apoptosis 
 
The mechanism of apoptosis is a specialized cascade of consecutive molecular events that 
have been categorized into two broad pathways: the extrinsic pathway (death receptor 
pathway) and the intrinsic pathway (mitochondrial pathway). Both pathways ultimately 
converge to activate effector caspases that are essential for the orchestrated sequence of 
biochemical events during programmed cell death (Choudhury et al. 2012).  
 
1.2.3.1 The caspases 
 
Caspases (cysteine aspartate specific proteases) are a family of cysteine proteases, which are 
expressed as inactive proenzymes (zymogens), also known as procaspases. Their structures 
can be classified into three domains: A N-terminal regulatory prodomain, the catalytic center 
containing the active site cysteine within a conserved pentapeptide sequence QACXG and a 
small C-terminal subunit (Figure 2).  
 
 
 
 
 
Figure 2. Classification of Caspases (Cysteine Aspartate acid proteases). 
Apoptotic caspases can be divided into two classes: initiator and executioner 
caspases. (From Tait and Green 2010).  
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The procaspases are activated by proteolytic cleavage at specific aspartate residues 
(Zimmermann et al. 2001, Choudhury et al. 2012). Upon maturation, the procaspases are 
proteolytically processed (aspartate cleavage site) between the large and small subunit, 
resulting in a small and large subunit that allows the formation of a heterotetramer composed 
of two small and two large subunits forming an active caspase (Figure 3) (Gewies 2003). 
 
 
 
 
 
 
 
 
Figure 3. Activation of procaspase-3 by cleavage. Schematic processing of 
caspases during activation. (From Zimmermann, Bonzon et al. 2001). 
 
In mammals, based on structure and function, caspases have been subdivided into two main 
categories (Figure 2). The first category is the initiator caspases, which include caspases 1, 
2, 4, 5, 8, 9, 10, 11 and 12, which contain a long amino- terminal prodomain that plays a 
regulatory role in activating downstream effector caspases. The second category is the 
executioner caspases, also called effector caspases, which include caspases 3, 6, 7 and 14 
contain a small prodomain and are responsible for cleavage of different cellular substrates. 
Caspases can be further classified into two subclasses. The first subclass is inflammatory 
caspases, which includes caspases 1, 4, and 5 that are involved in cytokine activation and the 
second subclass is other cellular caspases, including caspases 11, 12, 13 and 14, whose roles 
are less well established (Rajesh P. Rastogi 2009, Choudhury et al. 2012, Dipak D. Ghatage 
2012, Fuchs and Steller 2015).  
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1.2.3.2 Extrinsic pathway 
 
The extrinsic signalling pathway can be activated by ligation of death receptors (Fuchs and 
Steller 2015). These death receptors are part of the tumor necrosis factor receptor (TNF) gene 
superfamily (which includes, FasR, TNFR1 and DR4) and are localized on the surface of the 
cell then became active through binding specific ligands such as Fas ligand (also called 
CD95L), TNF alpha and TRAIL (also known as Apo2L). Subsequently, a conformational 
change exposes the death domain that allows the recruitment of adapter proteins (such as 
FADD or TRADD dependent on the active receptor), forming the Death Inducing Signalling 
complex (DISC).  DISC can associate with procaspase 8, resulting in autocatalytic activation 
of procaspase 8. Active caspase 8 can then induce the initiation of apoptosis by cleavage and 
activation of effector caspases (caspases 3, 7 and 6) (Figure 4) (Gewies 2003, Elmore 2007, 
Choudhury et al. 2012). 
 
Figure 4. Receptor-mediated caspase activation at the DISC. Upon ligation, 
the trimeric death receptor recruits adaptor molecules via its cytoplasmic death 
domains (DD). Besides possessing DDs, the adaptors additionally contain death 
effector domains (DED) which recruit procaspase-8 to the receptor complex, 
which now is called the death-inducing signalling complex (DISC). Procaspase-
8 is activated by autoproteolytic cleavage and forms the active caspase-8. The 
initiator caspase-8 cleaves and thereby activates effector caspases for the 
execution of apoptosis. (From Gewies 2003).  
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The crosstalk between extrinsic and intrinsic pathways can occur through caspase 8. Once 
caspase 8 is active, it can induce apoptosis through two parallel cascades. Firstly, it can be 
directly cleave and activate effector-caspases in a regular cascade. Secondly, it can mediate 
the cleavage of a pro-apoptotic protein Bcl-2; Bid (a BH3 domain-only protein). Truncated 
Bid (tBid) can then be translocated to mitochondria to induce mitochondrial outer membrane 
permeabilization (MOMP). MOMP causes the release of cytochrome c, which can 
subsequently activate caspase 9 and effector caspase 3 (Figure 5) (Tait and Green 2010, 
Choudhury et al. 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Intrinsic and extrinsic pathways of apoptosis. a) Intrinsic apoptotic 
stimuli, such as DNA damage or endoplasmic reticulum (ER) stress. b) The 
extrinsic apoptotic pathway is initiated by the ligation of death receptors with 
their cognate ligands. Crosstalk between the extrinsic and intrinsic pathways 
occurs through caspase 8 cleavage and activation of the BH3-only protein BH3-
interacting domain death agonist (BID), the product of which (truncated BID; 
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tBID) is required in some cell types for death receptor-induced apoptosis. (From 
Tait and Green 2010).  
 
1.2.3.3 Intrinsic pathway 
 
The intrinsic signalling pathway is activated by different signals coming from inside of the 
cell, such as strong DNA damage, radiation, toxins, hypoxia, hyperthermia, viral infections, 
and free radicals (Elmore 2007, Fuchs and Steller 2015). Mitochondria play an important 
role in this pathway, as they are crucial to induce the caspase-cascade activation and contain 
pro-apoptotic proteins in the intermembrane mitochondria space (IMS), between the inner 
and outer membranes of the mitochondria (IMM and OMM, respectively) (Tait and Green 
2010, Choudhury et al. 2012). All of the above-mentioned stimuli cause changes in the 
mitochondrial outer membrane permeability (MOMP). MOMP generates an opening of the 
mitochondrial permeability transition pore (MPT), also called PT pore resulting in a loss of 
the mitochondrial transmembrane potential, and stimulating the release of the sequestered 
pro-apoptotic proteins Apoptosis Inducing Factor (AIF), Smac/DIABLO and cytochrome C 
in the cytosol (Elmore 2007). Once the mitochondria release cytochrome c, it binds the 
apoptotic protease-activating factor 1 (APAF1) which allows the association of procaspase 
9. When cytochrome c is associated with APAF1, a conformational change leads to 
oligomerization and formation of a multiprotein complex termed apoptosome. The 
apoptosome induces cleavage and activation of caspase 3 and caspase 7, resulting in 
induction of apoptosis (Tait and Green 2010, Choudhury et al. 2012). MOMP is a tightly 
regulated process controlled by interactions between pro- and anti-apoptotic members of the 
B-cell lymphoma 2  family (BCL-2) (Figure 6) (Tait and Green 2010). 
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Figure 6. Intrinsic apoptosis pathway. Cytochrome c is a protein released from 
the mitochondria that binds to Apaf-1 and procaspase-9, in order to form the 
apoptosome, that then actives caspase-9 and effector caspases. (From Dipak D. 
Ghatage 2012). 
 
1.2.4 Regulatory mechanisms of apoptosis 
 
The control and regulation of apoptotic mitochondrial events are mediated by members of 
the Bcl-2 family proteins (Cory and Adams 2002). Tumor suppressor protein, p53 is an 
important pro-apoptotic factor that has a specific role in regulating the Bcl-2 family by 
activating the transcription of positive regulators such as DR-5 and Bax (Elmore 2007, 
Ouyang et al. 2012). Moreover, the PT pore formed during MOMP is due to the action of 
pro-apoptotic members of the Bcl-2 family, which in turn are activated by apoptotic signals 
such as cell stress, free radical damage or growth factor deprivation (Choudhury et al. 2012).  
 
1.2.4.1 The BCL-2 family 
 
The Bcl-2 family proteins were discovered as an oncogene in follicular B-cell lymphoma that 
inhibited cell death. This finding demonstrated for the first time that the promotion 
tumorigenesis is not only based on uncontrolled cell growth, but also depends on the ability 
to block apoptosis (Zimmermann et al. 2001, Gewies 2003). The Bcl-2 family has emerged 
as a critical regulator of apoptosis whose increased expression may lead to cancer and  
resistance to chemotherapy (Ouyang et al. 2012).  The Bcl-2 family regulates apoptosis by 
controlling the mitochondria membrane permeability (MOMP), and members of the Bcl-2 
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family may possess pro-apoptotic or anti-apoptotic activity (Elmore 2007, Choudhury et al. 
2012). 
 
The Bcl-2 family is composed of 25 pro-apoptotic and anti-apoptotic members containing 
one or more Bcl-2 homology (BH) domains. These proteins are divided according to their 
function into two main categories. The first category is anti-apoptotic proteins presenting 
four BCL-2 homology domains including BCL-2, MCL-1, A1/Bfl-1, Bcl-B/Bcl2L10 and 
BCL-xL (BCL extra-large). Anti-apoptotic Bcl-2 family members prevent apoptosis by 
inhibiting their pro-apoptotic partners via protein-protein interactions (Zimmermann et al. 
2001, Goldar et al. 2015). The second category is the pro-apoptotic Bcl-2 family proteins, 
which are sub-classified into two groups according to their structure. Group A, proteins 
having multiple BH domains (effector proteins) including: BAX, BAK, and BOK (BCL-2 
related ovarian killer) and group B, proteins having only the BH3 domain, including: BID, 
BIM, PUMA, NOXA, BIK, BAD, HRK, and BMF (Figure 7) (Goldar et al. 2015). 
 
 
 
 
 
 
 
 
Figure 7. BCL-2 family of proteins. The B cell lymphoma 2 (BCL-2) family 
of proteins is divided into three groups based on their BCL-2 homology (BH) 
domain organization. Anti-apoptotic BCL-2 proteins and Pro-apoptotic BCL-2 
proteins can be sub-divided into effectors (the proteins that actually cause 
mitochondrial outer membrane permeabilization (MOMP)) or BH3 only (the 
proteins that relay the apoptotic signal to the effectors). (From Tait and Green 
2010). 
 
Following death stimuli, pro-apoptotic proteins can undergo post-translational modifications 
such as dephosphorylation and subsequent cleavage that allow their activation and 
translocation to the mitochondria to initiate apoptosis (Ouyang et al. 2012). Therefore, pro-
apoptotic BH3-only proteins act as a sensor of these apoptotic signals that permit the 
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activation of multidomain proteins like Bax and Bak which subsequently perform a pore (PT) 
on the outer membrane of mitochondria that allow the release of cytochrome c and other 
mitochondrial proteins. These proteins are apoptosis-inducing factor (AIF), endonuclease G, 
Smac/DIABLO (second mitochondria-derived activator of caspase/direct IAP-binding 
protein with low PI) and the serine protease Omi/HtrA2 (Braun et al. 2013, Goldar et al. 
2015). Once these mitochondrial proteins are released into the cytosol, they can induce the 
caspase-cascade activation through repression of the inhibitor of Apoptosis proteins (IAP) in 
the case of Smac/DIABLO and Omi/HtrA2 (Gustafsson and Gottlieb 2008, Vande Walle et 
al. 2008). In addition, AIF and endonuclease G may also cause cell death in a caspase-
dependent manner or in a caspase-independent manner based on the cellular context (Arnoult 
et al. 2003, Prabhu et al. 2013).  
 
Another important pro-apoptotic BH3-only protein is Bim, well known as an efficient killer 
that can potentially induce cell death. Bim is essential for initiating intrinsic apoptosis 
pathway by apoptotic signals such as cytokine deprivation. These signals allow Bim to 
interact with all the anti-apoptotic Bcl-2 proteins (Mcl-1, Bcl-2, Bcl-xL, Bcl-w, and Bfl-1) 
and act in association with other partners like Noxa that selectively binds Mcl-1 and A1. 
Thus, a combination of selective binders and broader binders (Bim, Puma and tBid) promote 
apoptosis (Adams and Cory 2007, Sionov et al. 2015). 
 
In summary, apoptosis can be induced by numerous apoptotic stimuli through the intrinsic 
pathway by intracellular signals (eg. DNA damage), or through the extrinsic pathway by 
extracellular signals (eg. death ligands). The intrinsic pathway can be activated by death 
receptors that subsequently form the DISC (Death Inducing Signalling Complex) leading to 
the activation of caspase 8 that can cleave and activate caspase-effectors (Caspases 3, 6 and 
7) for induction of apoptosis. Simultaneously, caspase 8 can promote the activation of the 
intrinsic pathway through cleavage of a pro-apoptotic protein Bcl-2; Bid (tBid) which is 
subsequently translocated to the mitochondria to activate MOMP (strictly regulated by 
interactions between pro- and anti-apoptotic members of the BCL-2 family). Activation of 
MOMP in turn causes the release of cytochrome c into the cytosol to form the apoptosome 
in association with APAF1 that activates caspase 9 and effector-caspases.  
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Other cell signalling pathways have been reported to impinge on the core apoptotic 
machinery to modulate apoptosis. In relation to my research project, it has been shown that 
the Notch signalling pathway has an impact on cell death decisions (Zweidler-McKay et al. 
2005, Robert-Moreno et al. 2007). An example of a mechanistic link between the Notch 
pathway and apoptosis is the known Notch target gene, Hes1. Once activated by the Notch 
pathway, it can regulate apoptotic signals by interacting with the PARP1 protein, causing the 
permeabilization of the outer membrane mitochondria (MOMP) and the release of AIF 
(apoptosis inducing factor), resulting in activation of the caspase-cascade and subsequent cell 
death (Cande et al. 2002, Kannan et al. 2011, Prabhu et al. 2013). Another example of Notch 
signalling to promote apoptosis includes Notch signalling reducing the transcription of the 
pro-apoptotic Bcl-2 family member, Bcl-xL, thereby enhancing apoptosis (Robert-Moreno 
et al. 2007). The regulation of Notch receptors can also modulate apoptosis by inducing pro-
apoptotic BH3-only proteins, Bim and Noxa (Nickoloff et al. 2005, Konishi et al. 2010). 
 
1.3 THE NOTCH SIGNALLING PATHWAY  
 
More than 100 years ago, John S. Dexter discovered in Drosophila an irregular notched shape 
in the wings (Figure 8) (Dexter 1914). Later, in 1917, Morgan identified the alleles 
responsible for the notched wing phenotype for which he received the Nobel Prize in 1933 
(Morgan 1917).  Decades later, the gene was cloned in 1985 by Spyros Artavanis-Tsakonas 
and Michael Young, and the sequence was shown to be a cell surface receptor (Wharton et 
al. 1985). Furthermore, Artavanis-Tsakonas and Young characterized Notch as a regulator 
of cell-fate decisions (Artavanis-Tsakonas et al. 1999). Notch signalling has been shown to 
control several key cellular processes such as cell proliferation, differentiation, and apoptosis 
(Yao et al. 2007, Melino et al. 2008, Schwanbeck et al. 2011, Li et al. 2014). 
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Figure 8. Drosophila with Notches. Wing blade of a wild-type Drosophila 
melanogaster (left), and of a mutant with a partial loss of the NOTCH gene 
(right). The notches, which are absent in the wild type, but clearly visible at the 
border of the wing blade, have given the name to the implicated gene (Notch). 
(From Radtke and Raj 2003). 
 
1.3.1 Molecular biology of Notch Receptors 
 
The Notch family of genes is conserved evolutionarily among the species. In mammals, this 
pathway involves a group of four receptors called Notch (Notch1-4), while Drosophila 
melanogaster has one and Caenorhabditis elegans has two. Each receptor is a single-pass 
type I transmembrane protein and is composed of two domains (Figure 9) (Kopan and Ilagan 
2009, Pancewicz and Nicot 2011):  
 
 The extracellular domain: contain different repeats that share homology with 
epidermal growth factor (EGF). Notch1 and Notch2 have 36 EGF repeats and it has 
been reported that repeat 11 and 12 are important for ligand binding. Notch 3 and 
Notch 4 contain 34 and 29 repeats, respectively. The number of EGF repeats and their 
ability to bind to calcium ions play an important role in the affinity for Notch ligands 
(Kopan and Ilagan 2009, Ntziachristos et al. 2014).  
 
 The intracellular domain has several domains: RBPJ-k association module (RAM 
domain) and seven ankyrin repeats (ANK domain). Both domains are important for 
interacting with co-activators and forming the ternary complex with the mammalian 
CBF1/Drosophila Suppressor of Hairless/C. elegans LAG-1 protein (CSL; also 
known as RBPJ-k). Proline/glutamic acid/serine/threonine-rich, PEST domain 
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provides stability and is responsible for targeting the Notch intracellular domain 
(NIC) for degradation upon sel10 ubiquitin ligase recognition. Two nuclear 
localization sequences (NLS). The transcription transactivation domain (TAD 
domain), that is responsible for the activation of transcription, is strong in Notch1, 
weak in Notch2 and absent in Notch 3 and Notch 4 (Radtke and Raj 2003, Kato 2011). 
 
Notch receptors also have a heterodimerization domain (HD) and a negative regulatory 
region (NRR) that prevents activation of the receptor in absence of the ligand (Kopan and 
Ilagan 2009, Wang 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Structure of the four human Notch receptors. NEC: extracellular 
domain; NTM: transmembrane domain; EGF: epidermal growth factor; HD: 
heterodimerization domain; NIC: Notch intracellular domain; LNR: cysteine-
rich LNR repeats; TM: transmembrane domain; RAM: RBPjk-association 
module; NLS: nuclear localizing signals; ANK: ankyrin repeat domain; NCR: 
cysteine response region; TAD: transactivation domain; PEST: region rich in 
proline (P), glutamine (E), serine (S) and threonine (T) residues. (From 
Pancewicz and Nicot 2011). 
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1.3.2 Molecular biology of Notch Ligands 
 
Notch ligands are also transmembrane type I cell surface proteins. In mammalians, five Notch 
ligands have been reported which are classified into two families: Jagged family (JAG1-2) 
and Delta-like family (Delta-like 1, 3 or 4), based on the structural homology of the two 
Drosophila ligands, Serrate and Delta, respectively (D'Souza et al. 2008). Canonical Notch 
ligands possess a DSL domain (Delta/Serrate/LAG-2) and multiple EGF-like repeats but only 
the Jagged family and Dll-1 contain a DOS domain (Delta and OSM-11-like proteins). Both 
DSL and DOS domains are very important for receptor binding. In addition, members of the 
Jagged family have a cysteine-rich domain that, along with the DOS domain contribute to 
the structural diversity between the ligands (Figure 10) (Kume 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Domain organization of mammalian Notch ligands. All Notch 
ligands have an N-terminal domain, a DSL (Delta/Serrate/LAG-2) domain and 
EGF-like repeats. Jagged1 and Jagged2 contain a cysteine rich domain, whereas 
Jagged1, Jagged2, and Dll1 have two DOS (Delta and OSM-11-like proteins) 
domains located immediately following the DSL domain. (From Kume 2009). 
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1.3.3 Activation mechanism of Notch signalling pathway 
 
Initially, Notch receptors are synthesized as a single precursor in the Trans-Golgi, where they 
become a non-covalently linked heterodimer as a consequence of cleavage by a furin-like 
convertase at the S1 site (Schwanbeck et al. 2011, Ntziachristos et al. 2014). Subsequently, 
the receptor becomes glycosylated by O-fucosyltransferase and Fringe Family N-
acetylglucosaminidyl transferases. Following cleavage at S1 and glycosylation, the matured 
heterodimer Notch receptor is translocated to the cell surface (Kato 2011, Previs et al. 2015). 
Once on the cell surface, the activation of the Notch receptor depends on its interaction with 
one of its five canonical Notch ligands (JAG1, JAG2 and Delta-like 1, 3 or 4) (Kopan and 
Ilagan 2009, Wang 2011) in a neighbor cell. The interaction of Notch with its ligands initiates 
the signalling cascade by induction of a conformational change that allows proteolytic 
cleavage by the ADAM17 metalloprotease/TNFα converting enzyme (TACE) at the S2 site 
and subsequently endocytosis of the extracellular Notch domain in the signal-sending cell 
(Fortini 2009, Schwanbeck et al. 2011). Next, release of the intracellular active domain (NIC) 
is triggered by a third sequential proteolytic cleavage mediated by presenilin, the catalytic 
subunit of the γ-secretase complex, at the S3 site (Schroeter et al. 1998, De Strooper et al. 
1999, Okochi et al. 2002). The γ-secretase complex is composed of 4 subunits: Presenilin 
1/2, nicastrin (NCT), presenilin enhancer 2 (PEN2) and anterior pharynx-defective 1 
(APH1)) (Schroeter et al. 1998, De Strooper et al. 1999, Okochi et al. 2002, Ranganathan et 
al. 2011). Different compounds known as γ-secretase inhibitors (GSIs), classified into two 
types, can target γ -secretase cleavage at S3 pharmacologically. The two types are transition 
and non-transition state inhibitors. Treatment with GSI blocks the release of NIC from the 
plasma membrane, blocking the activation of Notch signalling (Ranganathan et al. 2011, 
Olsauskas-Kuprys et al. 2013). Once released, NIC is translocated to the nucleus where it 
acts as a transcriptional activator that interacts with the DNA-binding protein CSL and 
recruits co-activators such as mastermind-like (MAML1) and p300/CBP (CREB-binding 
protein) thereby regulating the transcription of their Notch target genes (Figure 11) (Kovall 
2008, Andersson et al. 2011, Bray 2016).  
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Figure 11. The canonical Notch signalling pathway. Notch receptor is 
glycosylated and cleaved by Furin at site 1 (S1). The interaction between Notch 
receptors and ligands on neighbouring cells results in the conformational change 
of receptor and the site 2 (S2) is cleaved by ADAM metalloproteases. Then, γ-
secretase complex-mediated cleavage at site 3 (S3) releases the Notch 
intracellular domain (NIC). NIC then translocates into the nucleus and binds to 
DNA binding protein CBF1/Su (H)/Lag-1 (CSL). Transcriptional co-activator 
Mastermind (MAM) recognizes the NIC/CSL complex. Ternary complex 
formation causes the release of co-repressor’s (Co-R) and recruit additional co-
activators (Co-A) to activate transcription of target genes. (From Kato 2011).  
 
In the absence of NIC, CSL acts as a transcriptional repressor through interactions with 
corepressors (Co-R). The Co-R including SMRT (silencing mediator of retinoid and thyroid 
receptors), SKIP (Ski-interacting protein), CtBP (C-terminal binding protein), Groucho/TLE 
(Transducin-like enhancer of split), CIR (CBF1-interacting corepressor) and SHARP 
(SMRT/HDAC1 (histone deacetylase 1) associated repressor protein (Figure 12) (Zhou et al. 
2000, Lai 2002, Jennings and Ish-Horowicz 2008, Fortini 2009). 
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Figure 12. Comparative view of the repression and activation complexes. 
Drosophila melanogaster. The CSL transcription factor acts as a bridging 
protein between the DNA and a complex of proteins intended to modify 
chromatin topology in a specific locus. CSL: CBF1/Drosophila Suppressor of 
Hairless/C. elegans LAG-1 protein; RAM: RBPjk-association module of NIC; 
ANK: ankyrin repeat domain of NIC; NIC: Notch intracellular domain; MAM: 
Mastermind; SKIP: Ski-interacting protein; CtBP: C-terminal binding protein; 
Groucho/TLE: Transducin-like enhancer of split. (From Contreras-Cornejo, 
Saucedo-Correa et al. 2016).  
 
1.3.4 Notch Target Genes 
 
The transcription of the Notch target genes depends on three features: ligand-receptor 
interactions, cell type (which also include several genes that participate in different cellular 
processes like metabolism, differentiation and regulation of the cell cycle) and the activity of 
the transcriptional complex, CSL-NIC (Ntziachristos et al. 2014, Contreras-Cornejo et al. 
2016).   
 
The CSL-NIC complex activates the expression of Notch target genes including 
transcriptional factors, Hes (Hairy in mammals and E (spl) in Drosophila) and Herp (Hes-
related repressor protein) (also known as Hey/Hesr/HRT/CHF/gridlock). Another Notch 
target gene includes: Cyclin D1, p21, NF-κB, pre-Tα (pre-T-cell receptor alpha chain), 
GATA3, NRARP, c-Myc and Deltex1 (Iso et al. 2003, Yin et al. 2010). The most well studied 
Notch target gene, and well known as a primary Notch effector, is HES/E (spl) which is part 
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of the basic helix-loop-helix (bHLH) family and binds DNA sequences as a dimer. This 
family of transcription factors is very important as effectors of the Notch pathway because 
they participate in the development of various organs (heart, skeletal muscles, pancreas) and 
cell types (Iso et al. 2003). 
 
1.3.5 Notch in tumorigenesis 
 
The contribution of the Notch signalling pathway to tumorigenesis is complex. Depending 
on the context, the Notch pathway has been shown to have an oncogenic or tumor suppressor 
effect (Ranganathan et al. 2011, Ntziachristos et al. 2014, Previs et al. 2015). The Notch 
signalling cascade shows an oncogenic effect in some cancers such as ovarian, prostate, 
nasopharyngeal, T-cell acute lymphoblastic leukemia (T-ALL), breast and sarcoma (Engin 
et al. 2009, Efferson et al. 2010, Wang et al. 2010, Wang et al. 2010, Chen et al. 2011, 
Hernandez Tejada et al. 2014). In apparent contrast, the Notch pathway also has a tumor 
suppressor effect on other cancers such as skin, endometrial, cervical, B-cell acute 
lymphoblastic leukemia (B-ALL) and lung (Sriuranpong et al. 2001, Nicolas et al. 2003, Yao 
et al. 2007, Dotto 2008, Kannan et al. 2011, Jonusiene et al. 2013). The role of the Notch 
pathway in cervical cancer remains ambiguous, as there is evidence that it can act as a tumor 
suppressor or as an oncogene (Maliekal et al. 2008). 
 
1.3.6 The role of Notch pathway in cervical cancer 
 
Cervical cancer (CC) is the fourth most common cancer in women and it is the seventh most 
common cancer worldwide, causing nearly 8% of all women deaths from cancer in 2012 
(Jemal et al. 2011, Cancer 2012, Ferlay et al. 2015). The main risk factor for the development 
of cervical cancer is high-risk human papillomaviruses (HR-HPVs) infection (zur Hausen 
2002). About 70% of all invasive cervical cancers are associated with the oncogenic HR-type 
16 HPV (HPV16) and 18 HPV (HPV18). Fifty percent of HPV-positive cervical tumors carry 
HPV16, whereas HPV18 is present in approximately 10-20% (zur Hausen 1996, Khan et al. 
2005, Smith et al. 2007, Guan et al. 2012, Goodman 2015). The development of cervical 
cancer develops through several steps that include. Firstly, HPV infects basal cells in the 
 
 
21 
21 
cervical epithelium. Secondly, the HPV DNA is integrated into the genome of the host cell. 
Thirdly, there is viral persistence (more than two years). Fourthly, there is progression to the 
neoplastic phenotype (classified 1 to 3, taking 3 to 5 years) and fifthly, invasive carcinoma 
develops (range 10 to 30 years) (zur Hausen 2002, Maglennon and Doorbar 2012, 
Steenbergen et al. 2014, Goodman 2015). 
 
Under normal conditions, the ectocervix is covered by a squamous epithelium and the 
endocervical canal is covered by a columnar epithelium. The basal layer of the endocervical 
epithelium contains precursor cells that have the ability to differentiate into squamous or 
columnar cells (Crum 2000, Allenspach et al. 2002). This region, known as the cervical 
transformation zone, is the site most susceptible to HPV infection, as well as the site for 
initiation of neoplastic transformation (Reid 1983, Doorbar et al. 2012, Lopez et al. 2012). 
HPVs expresses two oncoproteins, E6 and E7, which are essential for oncogenesis. The 
concerted action of E6 and E7 disrupts normal mechanisms of cell cycle regulation. In 
particular, E6 targets the p53 tumor suppressor protein, accelerating its degradation by the 
proteasome (Scheffner et al. 1990). The E7 oncoprotein functionally inactivates the pRb 
tumor suppressor by targeting to the proteasome for degradation (Dyson et al. 1989). pRb’s 
interaction with the E2F transcription factors inhibit their transcriptional activity of genes 
required for S-phase progression. The E7-induced degradation of pRb results in the release 
of E2F, allowing the expression of S-phase genes and progression of the cell cycle (Münger 
et al. 2001, Moody and Laimins 2010, Ghittoni et al. 2015). Although E6 and E7 are 
necessary for the induction and maintenance of the transformed phenotype, they are not 
sufficient to induce the development of cervical cancer. It has been shown that at least one 
other cellular/genetic alteration is necessary for the development of cancer. Accumulation of 
evidence suggests that aberrant Notch signalling is a cellular event that can play a role in 
cervical carcinogenesis (Zagouras et al. 1995, Daniel et al. 1997, Rangarajan et al. 2001, 
Talora et al. 2002, Lathion et al. 2003, Weijzen et al. 2003, Talora et al. 2005, Wang et al. 
2007).  
 
In human cervical cancer, it was discovered that Notch expression is reduced in invasive and 
metastatic cells, suggesting that down-modulation of Notch pathway is required in the 
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tumorigenesis process (Talora et al. 2002, Sakamoto et al. 2012). In cervical cancer cells, it 
has been reported that the activation of Notch pathway results in inhibition of tumor growth 
through the induction of apoptosis and cell cycle arrest (Yao et al. 2007). In particular, in 
HeLa cells, the activation of the Notch pathway has been shown that decrease cell 
proliferation and induces apoptosis (Wang et al. 2007).  
 
To conclude, apoptosis can be induced by the activation of the Notch signalling pathway 
following binding of a ligand, which results in cleavage of the Notch receptor by the γ-
secretase complex, releasing the active intracellular domain of Notch (NIC) and induction of 
Hes1 expression (Yao et al. 2007, Kannan et al. 2011, Wang 2011). Interestingly, the pro-
apoptotic transcription factor TAF6 (Bell et al. 2001) in HeLa cervical carcinoma cells can 
increase mRNA expression levels of Notch target genes and also pro-apoptotic genes as it 
was shown by microarray assays using Splice-Switching Oligonucleotides (SSOs) (Wilhelm 
et al. 2008, Wilhelm et al. 2010). Indeed, HeLa cells were shown to undergo apoptosis when 
TAF6 expression is triggered through SSOs (Wilhelm et al. 2010). The TAF6 pathway 
therefore represents a possible new therapeutic target for treating human cervical cancer cells. 
 
1.4 TRANSCRIPTION 
 
The regulation of transcription is a very important step in the control of cell identity, 
differentiation, growth and development (Grunberg and Hahn 2013). The transcription 
machinery initially recognizes double-stranded deoxyribonucleic acid (DNA), but only one 
strand serves as a template for transcription. The transcription process begins when a specific 
enzyme known as RNA polymerase (RNA pol) binds to the DNA strand template to initiate 
the production of complementary RNA (ribonucleic acid). When the RNA polymerases are 
active on DNA they form a complex with different factors that allow the transcription of a 
specific gene (Clancy 2008). These complex sets of factors are referred as general 
transcription factors (GTFs), which have several functions such as promoter recognition, Pol 
recruitment, interaction with regulatory factors, DNA unwinding and transcription start site 
(TSS) recognition (Hahn 2004, Thomas and Chiang 2006).  
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In eukaryotes, there are three different classes of RNA polymerases: RNA pol I transcribes 
genes encoding 18S and 28S ribosomal RNAs (rRNAs) within the nucleoli.  RNA pol III 
transcribe genes for 5S rRNA and transfer RNAs that play a role in the translation process 
and RNA pol II transcribing the messenger RNAs, which serve as templates for protein 
production, both localized at the nucleoplasm (Thomas and Chiang 2006, Clancy 2008). 
Since my work focused on the transcription factor TAF6, the focus here will be the 
mechanisms of transcriptional regulation by RNA pol II.  
 
1.4.1 Transcription by RNA Pol II 
 
Transcription by RNA pol II depends on a cascade of events, which are classified into three 
steps: initiation, which include the binding of activators to enhancers and the formation of 
the pre-initiation complex (PIC), elongation by RNA pol II and termination (Kandiah et al. 
2014). 
 
1.4.1.1 Initiation 
 
The initiation of transcription by RNAPII requires basal transcription factors known as 
TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH (Figure 13). 
 
 
 
 
 
 
 
Figure 13. Architecture of the basal PIC. (A) PIC model based on crystal 
structures and biochemical mapping. Note that the two Ssl2 domains (labeled 
Ssl2 C-term and Ssl2 N-term) of TFIIE, encircling promoter DNA at positions –
2 to +6 with respect to the human TSS at +1. From (Grunberg and Hahn 2013). 
(B) Model of the TFIID-based PIC, Cryo-EM reconstruction of the human TAF-
less PIC, with fitted atomic models. (From Louder, He et al. 2016).  
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1.4.1.1.1 Generalities of the basal transcription factors 
 
 TFIIA participates in transcription by stabilizing the binding between TBP (TATA-
binding protein) and the TATA box by regulating the dimerization of the TBP or 
TFIID that accelerate DNA binding. TFIIA also plays an important role in 
transcriptional activation of the TATA-less promoters and RNA pol III (Hoiby et al. 
2007). 
 
 TFIIB is a factor that is associated with TBP and RNA pol II that has four functional 
domains: N-terminus B-ribbon, reader, linker and core (contain two cyclin-like 
repeats), and all of them interact with RNA pol II. B-ribbon strongly involves RNA 
pol II, B-reader and linker form a hairpin, termed the B-finger in the RNA pol II and 
B-core, in addition to bind TBP-DNA. Thus, the conformation of TFIIB within PIC 
plays a crucial role in transcription activation, promoter recognition and start site 
selection (Reese 2003, Grunberg and Hahn 2013).  
 
 TFIID is a multi-subunit complex of mega-Dalton-sized that is thought to nucleate 
PIC formation on a core promoter by binding to the TATA box through its TBP 
subunit. TFIID also interacts with nucleosomes covalently modified and has been 
associated with enzymatic activities (post-translational histone modifications and 
transcription factors). This complex assumes a horseshoe-shaped structure containing 
three lobes (A, B and C). In the usual conformation, the lobe A is engaged to lobe C 
but the binding of TFIIA induces a conformational change that reorganizes the shape 
and, consequently, lobe A dislocates from lobe C to lobe B (Thomas and Chiang 
2006, Grunberg and Hahn 2013, Kandiah et al. 2014).    
 
 TFIIE, contain two TFIIEα and TFIIEβ subunits. TFIIEα containing an N-terminal 
WH and central Zn-ribbon, which are essential, and TFIIEβ containing tandem WH 
domains that are conserved. TFIIE function as a stabilizer of the non-template DNA 
strand and also interact directly with TFIIH because TFIIH is associated with the PIC 
just after TFIIE binds (Grunberg and Hahn 2013). 
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 TFIIF enters the PIC together with RNA pol II and contains two conserved 
polypeptides (Rap74/30), each containing an N-terminal dimerization domain and a 
C-terminal winged helix (WH). The dimerization domain binds to the lobe domain of 
RNA Pol II and the WH domain is bound to the protrusion of RNA Pol II (Grunberg 
and Hahn 2013). 
 
 TFIIH, is a large multi-subunit complex containing ten subunits, three of them contain 
ATP-dependent enzymatic activities, CDK7, the Pol II CTD kinase, Rad3/XPD, a 
DNA helicase and Ssl2/XPB (DNA translocase). The helicase subunits and kinase 
enzymatic activities are required for the initiation, elongation and promoter escape 
steps in RNA Pol II transcription. In addition to its role in DNA unwinding, TFIIH 
also has a role in the phosphorylation of the RNA pol II (Reese 2003, Grunberg and 
Hahn 2013). 
 
1.4.1.1.2 Mechanism of RNA Pol II initiation 
 
These accessory factors were defined as general transcription factors (GTFs) using the 
following nomenclature: TF represents the Transcription Factor, the Roman numeral II 
indicates the transcription driven by pol II, and the “letter” corresponds to the 
chromatographic fraction from which the specific GTF was isolated (Thomas and Chiang 
2006). The first step in the general mechanism is the recognition of the core promoter through 
PIC recognition of the different DNA elements located in the promoter region, known as a 
core promoter elements (CPEs) (Goodrich and Tjian 2010, Shandilya and Roberts 2012). 
These sequences are located upstream or downstream of the TSS on the target gene 
(Shandilya and Roberts 2012). One of the most studied CPE is the TATA box (TATAAA 
consensus sequence between 25 to 35 bases) upstream of the initiation site. However, not all 
Pol II promoters contain TATA sequences. TATA-containing promoters, which are actually 
the minority, account for 20-30% of the promoters in eukaryotes. In contrast, TATA-less 
promoters that generally direct the transcription of housekeeping genes and possess a 
heterogeneous TSS (Clancy 2008, Goodrich and Tjian 2010, Grunberg and Hahn 2013). The 
DNA sequence of the TATA box is recognized by TBP as part of the TFIID complex. TBP 
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possesses two domains: a highly conserved C terminus (TBPcore) that binds the TATA box 
and a divergent N terminus that is dispensable for viability. Once, TBP binds to the TATA 
sequence and induces a bend in the DNA that serves as a platform for the assembly of all 
GTFs and subsequent formation of PIC (Reese 2003, Shandilya and Roberts 2012). 
Consequently, the nucleation of PIC formation through the interactions of the TBP promoter 
is highly regulated (see below). 
 
 Positive regulation involves gene-specific activator proteins (activators) that increase 
the binding of TBP to promoters. The activator can induce multiple genes and 
multiple activators can also regulate a single gene. These activators are composed of 
an activation domain that allows association with different transcription factors and 
a promoter-targeting DNA-binding domain (Bhaumik 2011, Shandilya and Roberts 
2012). 
 
 Negative regulation involves the repression of the TBP-DNA binding activity 
through negative factors such as Mot1/BTAF1 and NC2 (Sikorski and Buratowski 
2009, Shandilya and Roberts 2012). 
 
During PIC formation, once TBP (subunit of TFIID) recognizes and binds to the TATA box, 
a sequential binding of TFIIA stabilizes the interactions of the TFIID-core promoter. TFIIB 
interacts with TBP and DNA promoter, and is assembled to the RNA pol II-TFIIF complex. 
However, transcription cannot begin until TFIIB, TFIIF and RNA pol II orient the DNA 
template, select the TSS and then TFIIE and TFIIH will be recruited into the PIC (table 1). 
TFIIH possesses a helicase activity and is therefore capable of catalyzing ATP-dependent 
melting of the promoter and making a transition from initiation of transcription to elongation 
(Reese 2003, Kandiah et al. 2014). Another important element for the transition is based on 
the length of the transcript that has to be about 25nt in order to stable transition complex that 
allows the elongation process. Otherwise, transcripts with less that 5nt result in an unstable 
transcription complex and therefore abortive initiation (Liu et al. 2011).  
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Protein Complex 
 
Functions 
 
RNA pol II 
12 Subunits; catalyzes transcription of all mRNAs 
and a subset of noncoding RNAs including snoRNAs 
and miRNAs 
 
TFIIA 
2–3 subunits; functions to counteract repressive 
negative cofactors like NC2; acts as a coactivator by 
interacting with activators and components of the 
basal initiation machinery 
 
 
TFIIB 
Single subunit; stabilizes TFIID-Promoter binding; 
helps in recruitment of TFIIF/Pol II to the promoter; 
directs accurate start site selection 
 
 
TFIID 
14 subunits including TBP and TBP Associated 
Factors (TAFs); nucleates PIC assembly either 
through TBP binding to TATA sequences or TAF 
binding to other promoter sequences; coactivator 
activity through direct interaction of TAFs and gene 
specific activators 
 
TFIIE 
2 subunits; helps recruit TFIIH to promoters; 
stimulates helicase and kinase activities of 
TFIIH; binds ssDNA and is essential for 
promoter melting 
 
TFIIF 
2–3 subunits; tightly associates with RNA Pol II; 
enhances affinity of RNA Pol II for TBP-TFIIB-
promoter complex; necessary for recruitment of 
TFIIE/TFIIH to the PIC; helps in start site selection 
and promoter escape; enhances elongation efficiency 
 
 
 
TFIIH 
10 subunits; ATPase/helicase necessary for promoter 
opening and promoter clearance; helicase activity for 
transcription coupled DNA repair; kinase activity 
required for phosphorylation of RNA Pol II CTD; 
facilitates transition from initiation to elongation. 
 
 
Table 1. Complexes involved in RNA Pol II PIC assembly. (From Sikorski 
and Buratowski 2009).  
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1.4.1.1.3 Mechanism of RNA Pol II elongation  
 
Once transcription starts, the double DNA helix unwinds and RNA pol II reads the template 
strand (Clancy 2008). During the early elongation phase, there is a checkpoint in which RNA 
pol II pauses in the promoter-proximal region (30–60 nucleotides downstream of the TSS).  
Such checkpoints serve as a quality control for the transcript 5′-capping and RNA Pol II 
modification before productive elongation. Paused RNA Pol II is associated with 
transcription factors (TFs) that function with negative elongation factor (NELF) and DRB-
sensitivity-inducing factor (DSIF) to stabilize the paused Pol II complex. The release of RNA 
pol II from the pause depends on the positive transcription elongation factor-b (P-TEFb) 
complex. P-TEFb associates with promoters through interactions with TFs and cofactors, and 
phosphorylates the carboxy-terminal domain (CTD) of Pol II (Jonkers and Lis 2015). Upon 
release of RNA pol II, productive elongation begins by adding nucleotides to the 3′ end of 
the growing strand typically at a rate of 22-25 nucleotides per second. However, these rates 
can be modulated by different factors such as histones and the number of exons in the gene 
(Clancy 2008, Jonkers and Lis 2015). 
 
1.4.1.1.4 Mechanism of RNA Pol II termination 
 
The CPF (cleavage and polyadenylation factor) pathway is responsible for the termination of 
mRNA transcription. This pathway contains a complex of CPF subunits, that interacts with 
the polymerase (Porrua et al. 2016).  
 
Initially, the RNA strand is cleaved by the CPF complex and this cleavage is coupled with 
the termination of the transcription that occurs in the consensus sequence AATAAA (Clancy 
2008). However, different factors are required to disassemble the elongation complex and 
the release of RNA Pol II. Processing and termination at the 3’-end are caused by several 
signals on the nascent RNA, which are recognized by the CPF complex (Figure 14). 
However, the complete mechanism for termination remains to be fully elucidated. Currently, 
there are two hypotheses. The first is termed the allosteric model and proposes that upon 
finding termination signals the polymerase undergoes a conformational change that allows 
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the enzyme to terminate. The second hypothesis is termed the torpedo model and proposes 
that the excision of the nascent transcript provides an entry point for a 5’–3’ exonuclease 
(XRN2) that degrades the nascent RNA still bound to the RNA Pol II and causes the 
termination (Porrua et al. 2016).   
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Figure 14. The transcription cycle. (A). Depending on the transcriptional 
competence of RNAPII, it can potentially enter a paused state. Presence of 
negative factors such as NELF and DSIF inhibits productive transcription 
initiation resulting in abortive transcription. Paused RNAPII is also enriched 
with phospho-Ser7 mark (orange balloon) at its C-terminal domain (CTD). The 
pTEFb complex alleviates this repression via phosphorylation of NELF and 
DSIF that results in dissociation of phosphorylated NELF from RNAPII, while 
DSIF may move along with the elongating RNAPII. (B). RNAPII can switch to 
a productive initiation mode. Active initiation is dependent on TFIIH-mediated 
promoter melting (red bubble) and phosphorylation of the CTD repeats (green 
balloon). Along with the phosphorylation of CTD, productive transcription 
initiation also requires the phosphorylation of TFIIB. The phospho-Ser5-CTD 
recruits capping enzyme to the 5′ region of nascent mRNA (green string) that 
triggers RNAPII-escape from the promoter of the gene. (C). Following promoter 
clearance, RNAPII proceeds to elongating the transcript while a part of the PIC 
components remains associated at the promoter forming a preinitiation, GTFs 
such as TFIIB, TFIIF and likely TFIIE fall off. The elongating RNAPII CTD 
repeat is progressively phosphorylated. (D). Once the RNAPII reaches a pause 
signal (poly A) at the gene terminal, 3′ end processing and termination specific 
complexes such as CPSF and CstF are recruited. The region already transcribed 
by RNAPII is efficiently reassembled into chromatin with the aid of histone 
chaperones and deacetylases (HDACs). (From Shandilya and Roberts 2012).  
 
1.5 TFIID 
 
TFIID, a complex of subunits, is a key part of the transcriptional complex and is composed 
of TATA binding protein (TBP) and a set of 13-14 TBP-associated factors (TAFs) (Green 
2000, Cler et al. 2009). TFIID binds to the DNA core promoter, via core promoter elements 
that can include the TATA box, the initiator (Inr), motif ten element (MTE), downstream 
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core promoter element (DPE), and the downstream core element motifs (Juven-Gershon and 
Kadonaga 2010). TFIID can also physically and functionally associate with trans-activating 
proteins that allow TFIID to play a role as a transcriptional co-activator. These TFIID-
activator models propose an induction of PIC assembly (Papai et al. 2011). TAFs, with a 
molecular weight between 15kDa to 250KDa, were initially named based on their different 
molecular weights, which differ between different species. In order to standardize the names 
of TAF protein, Tora and his colleagues proposed a common nomenclature (Table 2) 
(Thomas and Chiang 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Nomenclature of TAFs involved in RNA polymerase II-mediated 
transcription. (From Thomas and Chiang 2006).  
 
TAFs can also regulate transcription through recognition and binding to the core promoter 
(Malkowska et al. 2013). Associations among TAF-Inr, TAF-DPE and TAF-DCE 
(Downstream Core Element) can confer the ability of TFIID to recognize TATA-less 
promoters (Thomas and Chiang 2006). Many TAFs also have a histone fold domain that 
contributes to the recognition of core promoter elements. In order to maintain the integrity of 
the TFIID complex and to induce TAFs dimerization, the histone fold domain mediates many 
subunit interactions (TAF4-TAF12, TAF6-TAF9, TAF10-TAF3, TAF10-TAF8, and 
TAF11-TAF13) (Birck et al. 1998, Lavigne et al. 1999, Gangloff et al. 2000, Gangloff et al. 
2001, Gangloff et al. 2001, Gangloff et al. 2001, Thuault et al. 2002, Werten et al. 2002). 
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Moreover, crystallographic and in vitro studies have been shown a histone octamer-like TAF 
complex existing within TFIID that includes TAF4-TAF12 and TAF6-TAF9 (Hoffmann et 
al. 1996, Selleck et al. 2001).  
 
1.5.1 TAF6 
 
TAF6 is a transcription factor encodes by a gene containing 12300 base pairs, located on 
human chromosome 7. TAF6 is a subunit of the TFIID complex in the general transcription 
of RNA pol ll having two major domains, a HEAT repeat domain and a histone fold domain 
that can be divided into two sub-domains: a small middle domain and a larger domain. 
Mutations analyses demonstrate that the larger histone fold domain modulates the 
heterodimeric interaction between TAF6/TAF9 which in addition of TAF5 enhances the 
modulating effect of TAF6 (Scheer et al. 2012). It has also been reported that this dimeric 
complex (TAF6/TAF9) shows DPE-binding specificity in electrophoretic mobility shift 
assays (Figure 15) (Shao et al. 2005).  
 
 
 
 
 
 
 
 
Figure 15. Recognition of core promoter elements by TFIID and TFIIB. The 
interactions between TFIID and TFIIB with the core promoter elements. (From 
Thomas and Chiang 2006). 
 
One study revealed the crystal structure of TAF6 and showed that the HEAT repeat domain 
of TAF6 forms a homodimer that bridges TAFs (TAF1, TAF2 and TAF7) that interact with 
the downstream promoter (Louder et al. 2016). However, in that report they were not able to 
detect the density of the histone-fold domain of TAF6 that serves to interact with TAF9. 
Taking all together, available data suggest that the histone fold of TAF6 is flexible but not 
crucial for the structural integrity of the TFIID core (Louder et al. 2016). This coincides with 
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the fact that the human TAF6δ isoform, lacking a critical part of its histone fold domain, 
integrates into an active TFIID complex containing all TAFs except TAF9 (Figure 16) (Bell 
et al. 2001).  
 
 
 
 
 
 
 
 
Figure 16. TAF6 alternative splicing modified interaction with his dimer 
partner TAF9. The protein produced by the major splice variant, TAF6α, can 
interact with the TFIID subunit, TAF9 via its histone fold domain. In contrast, 
TAF6δ lacks 10 amino acids of helix 2 of its histone fold motif and therefore 
cannot interact with TAF9. (From Wilhelm, Pellay et al. 2008).  
 
Furthermore, TAF6 has been reported as essential for viability in yeast, Arabidopsis and 
Drosophila, as studies have shown that deletion of the TAF6 gene is lethal (Michel et al. 
1998, Aoyagi and Wassarman 2001, Lago et al. 2005). Our laboratory has recently also 
shown that TAF6 is essential for viability in human cells (Kamtchueng et al. 2014). Another 
feature of TAF6 is that it produces five isoforms as a result of alternative splicing (Figure 
17). The first three isoforms (TAF6α, TAF6β and TAF6γ) were detected by DNA sequence 
analysis (Weinzierl et al. 1993). The most abundant splicing variant is TAF6α, which encodes 
a 677 amino acid protein. TAF6β isoform encoding a 726 amino acid protein and TAF6γ 
isoform encoding a 667 amino acid protein. TAF6α, TAF6β and TAF6γ contain the first 
constitutive exon 2 and the alternative exon 2. TAF6β, unlike the TAF6α isoform, contains 
an upstream start codon that introduces 49 amino acids in addition to the NH2-terminal of the 
protein. However, TAF6γ exhibits 10 amino acids less than TAF6α due to the loss of the 
alternative part of exon 13. In addition, the other splicing variant that has been reported is the 
TAF6ε isoform encoding a 716 amino acid protein and the TAF6δ isoform that encodes a 
667 amino acid protein. Both isoforms (TAF6ε and TAF6δ) lack 10 amino acids after the 
alternative splicing that eliminate part of the exon 2 alternative. The difference between 
 
 
34 
34 
TAF6ε and TAF6δ is that TAF6ε contains the same 49 additional amino acids as TAF6β. In 
the case of TAF6δ, the deletion of 10 amino acids disrupted the second helix of the histone 
fold domain. Therefore, it cannot interact with its TAF9 dimer partner, but can continue to 
interact with TFIID and other TAFs such as TAF1, TAF5 and also TBP (Weinzierl et al. 
1993, Bell et al. 2001, Wang et al. 2004). 
 
(A)                                                                           
 
 
 
 
 
 
 
           (B)  
 
 
 
 
 
 
 
 
 
Figure 17. Isoforms of TAF6. (A) Schematic representation of the five TAF6 
isoforms. Representation of the histone fold motif and the HEAT repeats (c-
terminal domain) are indicated by clasps. Narrow rectangles represent cDNA, 
thick rectangles indicate protein sequences and start codons (ATG) are indicated 
with arrows. (B) The region of the TAF6 pre-mRNA that includes two alternative 
5’ splice sites (SSs) that produce either, the constitutive α splice variant or the 
alternative δ splice variant is schematically depicted. The selection of an intron-
proximal α 5’ splice site (SS) results in production of the isoform of the major 
TAF6 isoform (at right), whereas the selection of the proximal δ 5’ SS results in 
the production of the minor δ isoform (at left). The SSOs that base pair with the 
alternative exon forces splicing from the distal 5’ SS and induces the expression 
of the endogenous TAF6d isoform (at left). (Adapted from Wang, Nahta et al. 
2004, Wilhelm, Pellay et al. 2008). 
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1.5.2 TAF6δ 
 
It has been reported that the TAF6δ isoform is specifically expressed in apoptotic conditions 
(Bell et al. 2001). The fact that TAF6δ is generated from TAF6 pre-mRNA alternative 
splicing has been demonstrated by using an experimental system termed SSOs (splice-
switching oligonucleotides that act by hybridizing to pre-mRNA sequences and blocking 
access to transcript by splicing factors) (Kole et al. 2004, Bauman et al. 2009). SSOs can be 
used to force the expression of the endogenous TAF6δ isoform (Figure 17B). The SSOs 
oligonucleotides bind the alternative exon 2 and interfere with the normal functioning of the 
spliceosome, which means that the oligonucleotide induces the skip of the alternative exon 
2, thus resulting in a short RNA (δ isoform). Contrast microscopy showed that the expression 
of TAF6δ resulted in loss of cell adhesion and cells with apoptotic characteristics, such as 
membrane blebbing. It was further demonstrated that TAF6δ increased cell death in several 
cancer cell lines (HeLa, Saos-2, H1299, HL-60, A549 and HCT-116) (Wilhelm et al. 2008). 
In addition, SSOs RNA technology showed that TAF6δ can control apoptosis independently 
of the tumor suppressor p53 (Wilhelm et al. 2008). Transcriptome analysis performed in our 
laboratory showed that endogenous TAF6δ defined a pro-apoptotic transcriptome signature 
(Wilhelm et al. 2010). The TAF6δ-driven transcriptome landscape showed statistically 
significant enrichment of genes acting in several different pathways, including the Notch 
pathway, oxidative stress, integrin’s, p53, apoptosis and angiogenesis (Figure 18). 
 
 
 
 
 
 
 
 
 
Figure 18. A model for the TAF6δ pathway. A hypothetical model coupling 
changes in gene expression to cell death via the TAF6δ pathway of apoptosis. 
(From Wilhelm, Kornete et al. 2010).  
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Our laboratory has recently shown that the TAF6δ-driven transcriptome signature is distinct 
from that observed when the major TAF6 isoform, TAF6α was depleted by siRNA 
(Kamtchueng et al. 2014). These results underscore the importance of TAF6δ induction as 
opposed to the simple loss of total TAF6 protein in the control of a physiological cell death 
transcriptional program. While TAF6δ’s role is the induction of apoptosis is well established, 
the physiological role of TAF6δ in living organisms remains obscure. Since the genes of the 
Notch pathway were the most statistically significant enriched in response to TAF6δ 
expression, we hypothesized that TAF6δ may influence and possibly activate the Notch 
pathway. Another clue suggesting the activation of the Notch pathway by TAF6δ was the 
observation that the classical Notch target gene, Hes1 is induced by TAF6δ (Wilhelm et al. 
2010). However, the specific implication of the Notch signalling pathway and the molecular 
mechanism for apoptosis induction by TAF6δ are presently unknown. Consequently, in this 
study, we asked whether TAF6δ induction can activate Notch signalling and whether Notch 
signalling contributes to TAF6δ-dependent apoptosis. The results of my master’s work 
extend our laboratory’s earlier work showing that genes from the Notch signalling pathway 
are overrepresented in the TAF6δ-driven transcriptome signature in HeLa cells (Wilhelm, 
2010), by revealing that the regulation of Notch-related genes occurs in cancer cell lines of 
multiple tissue origins. Most importantly, my results show that Notch2 is activated by 
TAF6δ, and that Notch signalling can contribute to TAF6δ-induced apoptosis. 
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2 HYPOTHESIS 
 
Apoptosis plays an important role in the formation of organs and tissues (Rajesh P. Rastogi 
2009). Additionally, several signalling pathways can activate the apoptotic process, including 
the Notch pathway (Zweidler-McKay et al. 2005, Robert-Moreno et al. 2007). However, 
Notch signalling implication in tumorigenesis is not well defined yet. Depending of the 
context, Notch pathway has been demonstrated to have oncogenic or tumor suppressor effect 
(Previs et al. 2015). This signalling cascade shows a tumor suppressor effect in cervical 
cancer (Yao et al. 2007). Indeed, it was discovered that Notch expression is reduced in 
cervical cancer cells, suggesting that specific down-modulation of Notch pathway is required 
in the tumorigenesis process (Talora et al. 2002, Sakamoto et al. 2012). In addition, in 
cervical cancer cells, it has been reported that the activation of the Notch pathway results in 
the inhibition of tumor growth through induction of apoptosis and cell cycle arrest (Yao et 
al. 2007). In particular, in HeLa cells, it has been shown that activation of the Notch pathway 
decreases cell proliferation and induces apoptosis (Wang et al. 2007). 
 
TFIID, a macromolecular complex, is a fundamental part of the transcriptional complex and 
it is composed of TATA binding protein (TBP) and a set of 13-14 TBP-associated factors 
(TAFs) (Cler et al. 2009). TAFs can regulate transcription through recognition and binding 
to the core promoter (Malkowska et al. 2013), and it has been reported that the TAF6δ 
isoform generated by the alternative splicing of TAF6 pre-mRNA is expressed only under 
apoptotic conditions (Bell et al. 2001). Furthermore, it was demonstrated that TAF6δ induces 
cell death in several cancer cell lines (HeLa, Saos-2, H1299, HL-60, A549 and HCT-116), 
independently of the p53 tumor suppressor (Wilhelm et al. 2008). Importantly, the 
endogenous expression of TAF6δ on the global transcriptome landscape reveals a statistical 
enrichment in several genes that act in different pathways including the Notch pathway 
(Wilhelm et al. 2010). In contrast, with a transcriptome reporting the depletion of the major 
TAF6 isoform, TAF6α does not result in significant changes in genes in the Notch pathway 
(Kamtchueng et al. 2014). In our previous microarray data, we observed increases in genes 
of the Notch pathway, including the most studied Notch target gene, Hes1. However, the 
whether or not the Notch signalling pathway is activated by TAF6δ, and whether Notch 
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signalling contributes to the induction of apoptosis by TAF6δ are presently unanswered 
questions. Therefore, my project was to test the hypotheses that TAF6δ activates Notch 
signalling and whether the Notch pathway participates in the induction of apoptosis.  
 
In order to verify this hypothesis, we have two general objectives: 
A) General Objective  
 
Does TAF6δ expression cause activation of the Notch pathway? 
 
B) General Objective  
 
Can Notch activation contribute to TAF6δ-dependent apoptosis? 
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3 MATERIAL AND METHODS 
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3.1 Cell culture 
 
HeLa cells were grown in DMEM (Dulbecco’s Modified Eagle Medium) containing 2.5% 
CS (calf serum) and 2.5% FBS (foetal Bovine serum). Hs-578-T and MDA-MD-231 cell 
lines were cultured in DMEM with 1% Glutamine and 10% and 15% of FBS, respectively. 
Panc1 cells were grown in DMEM supplemented with 10% FBS, 1% Glutamine, 1% Sodium 
Pyruvate and 1% Hepes (table 3).  
   
Table 3. Cancer cell lines used in this study 
Cancer cell 
line 
Origin Provider 
HeLa Cervix Adenocarcinoma Thanks to the IGBMC institute 
(Strasbourg) 
Hs-578-T Breast Carcinoma Thanks to Pr. Benoît Chabot 
 
MDA-MB-231 Breast Adenocarcinoma Thanks to Pr. Benoît Chabot 
 
Panc1 Pancreas Epithelioid Carcinoma Thanks to Pre. Marie-Josée 
Boucher 
 
3.1.1 Transfections with SSOs (Splice Switching Oligonucleotides) 
 
2’-O-methyl-oligoribonucleoside phosphorothioate antisense 20-mers were purchased from 
Sigma-Proligo, USA. “SSOs control” and “SSOs TAF6δ, also called SSOs T6-1” have been 
described previously (Wilhelm et al. 2008). “SSOs T6-3” 5’-
CUGUGCGAUCUCUUUGAUGC-3’ targets the 3’ part of the alternative exon 2 of TAF6 
and induces TAF6δ production. “Control SSOs” 5’-AUGGCCUCGACGUGCGCGCU-3’ 
and “Control SSOs-2” 5´ ACGGUCCGUUAGCGUGCCGC 3´ are a scrambled oligo’s used 
as a negative control.  
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The cells were seeded at densities of 70,000 cells/0.5ml in 24-well plates and cultured 
overnight at 37ºC with 5% of CO2. Twenty-four hours later the medium was replaced by 
350µl of Opti-MEM (Minimal Essential Medium) (Invitrogen) and put it back at the 
incubator at 37ºC with 5% of CO2 whereas the mixes where prepared. The SSOs were 
transfected with lipofectamine 2000 (Invitrogen). First 0.8µl of lipofectamine was mixed 
with 50µl of Opti-MEM for 5 minutes at room temperature while a second mix was prepared 
contain SSOs plus 50µl of Opti-MEM at a final concentration of 100 nM. Next, the 
lipofectamine mix were combining with SSOs mix for 20minutes at room temperature. 
Subsequently, 100µl of the complex (liposomes-SSOs) were added drop by drop to each well 
delicately. Eighteen to twenty-four hours after the cells were harvested for analysis. All 
transfections were performed in Opti-MEM. 
 
3.2 Blocking Notch pathway by GSI treatment 
 
DAPT (N-[N-(3, 5-Difluorophenacetyl)-L-alanyl]-S-phenyl glycine t-butyl ester) and S2188, 
γ-secretase inhibitors were purchased from Sigma, USA. They were used to block Notch 
signalling transduction mediated through γ-secretase cleavage of Notch receptor. Cells in 
logarithmic growth were seeded at densities of 70,000 cells/0.5ml in 24-well plates and 
cultured in the presence of the GSI (50µM DAPT or 15µM S2188) and control cells were 
treated with DMSO (Dimethyl sulfoxide) for 1h, before the SSOs were transfected. Eighteen 
to twenty-four hours later, the cells were harvest to analyze the expression of Notch ligands, 
receptors and target genes (mRNA levels) and Notch1-2, Hes1 (protein level) and apoptosis 
induction.  
 
3.2.1 Activation of Notch Pathway through EGTA treatment 
 
EGTA (ethylene glycol-bis (2-aminoethylether)-N, N, N’, N’-tetra acetic acid: 5mM) a 
calcium-chelator from Sigma Aldrich. It was used for 15 minutes to activate the cleavage of 
the Notch receptors then the medium was replaced by fresh culture media (DMEM) for 1h 
before harvest the cells. 
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3.3 Antibodies 
 
Mouse monoclonal antibody against TAF6δ (37TA1C2; 1:1200) have been described (Bell 
et al. 2001). Rabbit polyclonal antibody against Hes1 (AB5702; 1:2000) and mouse 
monoclonal antibody against TATA Box-binding protein; TBP (clone 5FT1-1C2; 1:2500) 
were purchased from Millipore. Rabbit monoclonal antibody against Cleaved Notch1 
(Val1744 (D3B8) #4147; 1:1000) and rabbit monoclonal antibody against Notch2 (D67C8 
#4530; 1:1000; it recognizes both the full-length and the transmembrane/intracellular region) 
were purchased from Cell Signaling Technology. Rabbit polyclonal antibody against Notch2 
(8926; 1:1000; the epitope is only exposed after gamma secretase cleavage) were purchased 
from Abcam. Secondary antibodies used in western blot: anti-mouse and anti-rabbit IgG-
horseradish peroxidase (HRP) were purchased from Jackson Immunoresearch Laboratories. 
Secondary antibodies used in immunofluorescence: Alexa Fluor 546 goat anti-mouse IgG 
(1:1200) and Alexa Fluor 488 goat anti-rabbit IgG (1:400) were purchased from Molecular 
Probes. 
 
3.4 Extraction of RNA 
 
The cells previously transfected were collected for RNA extraction. The Opti-MEM medium 
that contained the floating cells was placed in an Eppendorf tube. Two hundred and fifty 
microliters of Trizol (Invitrogen) were added to the wells in order to retrieve all the adherent 
cells for 5min at room temperature after which the Eppendorf with medium were centrifuged 
for 30 seconds at 10,000 rpm. The supernatant was discarded; the mix adherent cells-Trizol 
was added to the pellet. Subsequently, 50µl of chloroform were added, mixed vigorously and 
let it for 2 minutes on ice. Samples were then centrifuged for 15minutes at 13,000 rpm to 
separate the phases. The aqueous phase that contained the RNA was transferred onto 125µl 
of isopropanol, mixed and centrifuge for 15minutes at 13.000rpm to precipitate the RNA. 
The pellet obtained was washed with 1 ml of ethanol 75% and centrifuge for 5 minutes at 
8.000rpm. The pellet was then dried for 10 minutes at room temperature and resuspended 
with 12µl of nano water.  
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3.4.1 RT-PCR (Reverse transcription polymerase chain reaction) 
 
Total RNA was extracted using Trizol (Invitrogen) as previously described. 1µg of total RNA 
was reverse transcribed using MMuLV reverse transcriptase (from Catherine Desrosiers). 
1µg of total RNA was mixed to hybridize with 2µl of Oligo dT (20µM) at a final volume of 
12µl for 2 minutes at 95ºC. Then, 8µl of master mix (4µl of 5x MMuLV Buffer, 2µl of 
DNTP´s 10mM, 1µl of DTT (dithiothreitol) 5µM and 0.6µl of MMuLV reverse transcriptase) 
were added and complemented with nano water until final volume of 20µl for 1h at 42ºC. 
 
3.4.2 PCR (Polymerase chain reaction) 
 
The complementary DNA (cDNA) previously obtained was used as a template on the PCR. 
3μl of cDNA were mixed with 22μl of solution buffer that contained: 2.5μl of 10x PCR 
buffer, 0.5µl of DNTP´s 10mM, 0.25µl Taq DNA Polymerase (from Catherine Desrosiers) 
and 0.5µl of each oligo 20µM (T6-1B: 5´- ATGGGCATCGCCCAGATTCAGG -3´ and T6-
2E: 5´-AAGGCGTAGTCAATGTCACTGG-3´) that amplified TAF6α and TAF6δ. The 
reaction PCR conditions were: 95ºC, 3 min; denaturation; 25 cycles of 94ºC for 1 min; 
denaturation, 58ºC for 45 sec; hybridization, 68ºC for 50 sec; final extension at 68ºC for 5 
min. Primers used for amplification of both TAF6α and TAF6δ have been described 
previously (Wilhelm et al. 2008). The PCR products were qualitatively analyzed through an 
electrophoresis on polyacrylamide gel 15% to confirm TAF6δ induction after SSOs 
transfection in each experiment. The polyacrylamide gel was performing as a mix:  3ml of 
acrylamide 30%: bis acrylamide (30: 0.8), 1.2ml of TBE 5X (Tris base 0.09M, EDTA 0.5M 
and boric acid 0.089M), 42µl of Ammonium persulfate (APS), 2.2µl of TEMED and 
complemented with nano water until final volume of 6ml. 10µl of the PCR product was 
loading on the gel, migrated and stained with ethidium bromide (EtBr). The images were 
recorded using a UV photo-doc system. 
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3.4.3 qPCR (Real time PCR) 
 
Real time PCR was performed on cDNA previously obtained by RT-PCR. Real-time PCR 
was made in a final 20μl reaction containing 10 ng of cDNA with 10 μl of the 2X master mix 
buffer (50ml Stock Buffer: 600μl Tris pH 8.0 1M, 1 ml KCL 2.5M, 400μl MgCl2 1M, 2.84g 
Trealose (TRE222, Bioshop), 100μl Tween 20, 500μl bovine serum albumin (BSA) 20mg/ml 
(NEB #B9001S), 1μl SYBR® Green (Life Technologies # S7563)), 0.4µl of DNTP´s 10mM, 
0.6μl of each primer 5 μM, 0.2µl Klentaq (from Catherine Desrosiers) and 4.2μl of nano 
water, mixed in 96 well plates (PCR® microplate, 96 well Flat Top, clear (Axygen, INC, 
USA)). Real-time PCR relative quantification assay was running for 2 minutes at 95ºC, 
followed by 40 cycles of 15 seconds at 95ºC, 15seconds at 58ºC, and 20 seconds at 68ºC after 
15 seconds at 95ºC, 15 seconds at 60ºC, and 15 seconds at 95ºC. Relative quantity of target 
genes was calculated using the comparative CT (ΔΔCT) method using hRPLPO (large 
ribosomal protein) as the internal control. Primer sequences are listed in Table 4. The PCR 
products were run on a 2% agarose gel to confirm the size of the product. 
 
Table 4. Primer sequences, annealing temperatures and amplicon sizes for qPCR analysis 
used in this study 
Primer Sequence (5´-3´) 
Annealing 
temperature (°C) 
Amplicon 
size (pb) 
Dll1 ATGTGATGAGCAGCATGGATT 58 197 
  GGTGTGTGCAGTAGTTCAGGTC     
Dll3 CCCTTCCTCGATTCTGTCCG 60 160 
  ACCTCCTCAAGCCCATAGGT     
Dll4 GCC AGA GGC CTT GCC ACC AG 63 183 
  CGC TTC TTG CAC AGG CGG GA     
Jagged1 AAC GAC CGC AAC CGC ATC GT 63 170 
  TTC AGC GTC TGC CAC TGC CG     
Jagged2 CGG CGT CAA CTG GTT CCG CT 63 288 
  CCG TGT GGG AAC GGA GTG CC     
Notch1 GCG GTC CCA ACT GCC AGA CC 63 284 
  GCA CGG GCT CAG AAC GCA CT     
Notch2 CCCACAAAGCCTAGCACCAA 60 177 
  ATTGGAAGGCACCTTGTCCC     
Notch3 AGC GTT GTC AGC GGT GGA GC 63 488 
  CGT CGC CCT GTG GTG GTG TC     
Notch4 ACTTGGTCCGTAGACTTGGC 58 521 
 
 
45 
45 
  TCTGCTCTGGTGGGCATACAT     
Hes1 TGCTACCCCAGCCAGTGTCAA 58 150 
  AGAGCATCCAAAATCAGTGTTTTCAGC     
Hey1 CTGAGCAAAGCGTTGACAAA 60 212 
  TCCACCAACACTCCAAATGA     
Hey2 AGGCTACTTTGACGCACACG 58 153 
  CAAGTGCTGAGATGAGACACAAG     
Bim ATGTCTGACTCTGACTCTCG 58 173 
  CCTTGTGGCTCTGTCTGTAG     
Noxa TCCTGAGCAGAAGAGTTTGG 58 163 
  GGAGATGCCTGGGAAGAAGG     
Acrc CTCATGGTGACGCATGGAAG 58 144 
  AGCAGCCAATCCTCGTTTTG     
hRPLPO GCAATGTTGCCAGTGTCTG 58 142 
  GCCTTGACCTTTTCAGCAA     
 
3.5 Western Blot 
 
HeLa Cells previously transfected were collected for protein extraction. Floating cells were 
transferred in an Eppendorf. The cells were then washed with 500μl of PBS 1X (NaCl 
137mM, KCl 2.7mM, Na2HOP4 4.3mM and KH2PO4 1.47mM pH 7.4) and centrifuged twice 
for 1 minute at 4000rpm while the monolayer cells were lysed in 20µl of white laemmli 
sample buffer 1.5X (150mM Tris, 15% glycerol and 3.75% SDS) after the pellet obtained by 
centrifugation was mix with the lysates-cells and boiled for 5 minutes at 95ºC and sonicated 
(under amplitude of 90 for 2.5 minutes with 10 seconds break every 20 seconds). 
Subsequently, protein concentrations were determined with BCA Protein Assay Kit 
(Thermofisher, scientific; #23221). Five to twenty micrograms of protein lysates were 
electrophoresed with migration buffer (Tris-base 0.025M, glycine 0.192M and SDS 0.1%) 
on 7.5% and 12% SDS-PAGE (Resolving buffer: Tris 1.5 M pH8.8, SDS 0.4% and 
acrylamide/bisacrylamide (30:0.8) and Stacking buffer: Tris 0.1M pH 6.8, SDS 0.4% and 
acrylamide/bisacrylamide (30:0.8)) at 100 volts during 10 minutes and after 150Volts for 40 
minutes, before transferred to Nitrocellulose membrane (PROTRAN, PerkinElmer) with 
transfer buffer (Tris-base 0.01M, glycine 0.077M and ethanol 20%) during 1h at 115Volt. 
PBS-Tween 0.05% containing 5%nonfat milk was used to block nonspecific binding for 1h 
at room temperature. Membranes were incubated overnight at 4ºC with previously described 
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primary antibodies against Hes1, Cleaved Notch1, Notch2 or TBP. Next day, the membranes 
were washed 3 times with PBS-Tween 0.05% for 5 minutes and a second incubation was 
conducted with HRP-conjugated secondary antibodies (Jackson Immunoresearch 
Laboratories) for 2h at room temperature. The bound antibodies were visualized using an 
enhanced chemiluminescence kit (Western Lightning Plus-ECL; PerkinElmer).  
 
3.6 Immunofluorescence 
 
HeLa cells (60.000cells/0.5ml) were grown on cover slips pre-treated with 200µg/ml of L-
polyLysine (Sigma #P6282) for 24h and then washed twice with phosphate-buffered saline 
(PBS) before the SSOs were transfected. 18h after cells were washed twice with PBS and 
subsequently fixed in 2% of paraformaldehyde (PFA) for 6min, permeabilized with PBS-
0.1% Triton X-100 (PBS-Tx twice for 10 min and then incubated for 30 min with blocking 
buffer (PBS-Tx containing 1% bovine serum albumin (BSA) and 0.5% fish gelatin (Sigma-
Aldrich)). Cells were then incubated one hour at room temperature, with each of the 
following antibodies diluted in blocking buffer; anti-TAF6δ (37TA1C2: 1:1200), Alexa 
Fluor 546 goat anti-mouse IgG (1:1200) secondary antibody (Molecular Probes), anti-Notch2 
(Ab8926: 1.1000), Alexa Fluor 488 goat anti-rabbit IgG (1:400) secondary antibody 
(Molecular Probes), followed by three washes with permeabilization buffer between each 
antibody. Cells were then treated with Hoechst 33342 (2 µg/ml) and visualized by 
fluorescence microscopy (Leica DM2500 Optigrid). Total nuclear fluorescence analyses 
were performed by CellProfiler 2.1.1 software, http://cellprofiler.org/previous_releases/.   
 
3.7 Apoptosis assays 
 
HeLa cells were seeded at densities of 70,000 cells/0.5ml in 24-well plates and cultured 
overnight at 37ºC. After being treated with GSI (DAPT) and SSOs were transfected as 
described above. Eight-teen hours after, floating and trypsinized cells were collected, washed 
with cold PBS and centrifuged at 8000 rpm for 1 min at room temperature. The cell pellet 
was fixed using 3% formaldehyde, incubated 10 min at 37ºC and centrifuged twice at 8000 
rpm for 1 min at room temperature. Then, the pellet was permeabilized with 300µl of cold 
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Methanol 100% for 30 min on ice and subsequently blocking buffer that contained (PBS1X; 
BSA 0.5%) was added. The cells were next centrifuged twice before resuspended in 100µl 
of blocking buffer that contained cleaved caspase-3 antibody  diluted (1:2000) (Cell 
Signaling Technology; #9661) and incubated overnight at 37ºC. 1 ml of blocking buffer was 
then added to the cells and centrifuged. The pellet was resuspended in 100µl of blocking 
buffer that contained secondary antibody (α-Rabbit- Phycoerythrine; Jackson 
Immunoresearch Laboratories) diluted (1:100) and incubated for 60min at room temperature 
in the dark. Subsequently, 1 ml of blocking buffer were added to the cells and centrifuged. 
Then stained cells were resuspended in 100µl of PBS and analysis were performed using 
Flow Cytometry (Becton Dickinson FACScan) following the manufacturer’s 
recommendations. 
 
3.8 Microarray Analysis of Gene Expression 
 
Transcriptome analysis was performed as we previously detailed (Wilhelm et al. 2008), using 
the NeONORM normalization method (Noth et al. 2006). Free parameter k was set to 0.2. 
The AB1700 data generated for this study on an Applied Biosystems Microarray platform 
were annotated according to the published procedure (Noth and Benecke 2005). For 
comparative cellular process inference analyses, the combined TAF6δ pathway activation 
and inhibition of the Notch pathway were performed with Gene Ontology (GO) and KEGG 
annotations as we previously detailed (Wilhelm et al. 2010). P-values were determined using 
a hypergeometric distribution and a null hypothesis of a random set of genes with identical 
size. Microarray data for the gene sets analyzed herein are provided in Additional Files. The 
transcriptome-wide microarray data for all of the experiments described here were deposited 
in the database http://mace.ihes.fr under accession numbers: Notch signature: 2547351260; 
TAF6δ signature: 2937831950.  
 
3.9 Statistical analyses 
The Student´s t-test for estimation of statistical significance for all data except the microarray 
analysis. P-values within (P <0.05) are marked by one asterisk. Whole genome gene 
expression data were analyzed using the CDS test (CDS: a fold-change based statistical test 
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for concomitant identification of distinctness and similarity in gene expression analysis 
(Tchitchek et al. 2012), dimensionality reduction was performed using SVD-MDS (Becavin 
et al. 2011). 
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4 RESULTS 
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A) General Objective  
Does TAF6δ expression cause activation of the Notch pathway? 
4.1 Objective 1: To determine the impact of Notch pathway inhibition on the TAF6δ-
driven transcriptome changes in HeLa cells. 
 
4.1.1 Notch signalling impacts TAF6δ-driven transcriptome changes  
 
Given that TAF6δ regulates the expression of genes in the Notch pathway, including classical 
direct Notch target genes such as Hes1 (Wilhelm et al. 2010), we sought to determine whether 
Notch signalling is activated by TAF6δ expression. If the Notch pathway is activated by 
TAF6δ, Notch activity could potentially contribute to the transcriptome changes induced by 
TAF6δ. To directly test the impact of Notch signalling on TAF6δ-driven transcriptome 
changes we employed microarray technology to measure transcriptome-wide gene 
expression, together with SSOs (Splice-Switching oligonucleotides) to induce the expression 
of the endogenous TAF6δ splice variant as previously reported (Wilhelm et al. 2008). Notch 
signalling was inhibited using the GSI (γ-secretase inhibitor) in HeLa cervical carcinoma 
cells. We measured the impact of GSI (S1288) treatment on control cells (treated with a 
scrambled SSOs) and on cells where SSOs were used to induce TAF6δ. GSI treatment of 
control cells caused both increases and decreases in gene expression with the majority of 
statistically significantly changed transcripts displaying increased expression (Figure 19A, 
left heat map red versus blue). In contrast, GSI treatment of cells where endogenous TAF6δ 
was induced showed a reduction in expression of the majority of regulated transcripts (Figure 
19A, right heat map red versus blue), suggesting that TAF6δ-induced gene transcription is 
selectively reduced when Notch signalling is inhibited. Further analysis of the transcriptome 
changes showed that 491 genes were statistically significantly regulated by TAF6δ and, of 
these, only 116 remained significantly changed in the presence of GSI (Figure 19B). 
Globally, the majority of the 491 TAF6δ-regulated genes had a reduced change in expression 
(Figure 19C, shown in red). Despite the fact that γ-secretase inhibition resulted in the reduced 
induction of numerous TAF6δ-regulated genes, the induction of a subset of TAF6δ-
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dependent genes was augmented in the presence of GSI (Figure 19 C, shown in green), ruling 
out the possibility that GSI could cause a non-selective reduction in transcription. 
We performed gene ontology analysis on the 375 genes that were TAF6δ-regulated and 
whose change in expression was reduced by GSI treatment to shed further light on the 
function of genes in that subset. The ontology analysis revealed a statistically significant 
enrichment of genes in the ontology-classes of chromatin packaging, cell proliferation, and 
nucleoside/nucleotide metabolism (Figure 19D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure. 19. A fraction of TAF6-regulated transcription depends on Notch 
signalling. (A) Heat map of statistically significantly (P <0.05) regulated genes 
in response to the GSI (S2188) (lanes 2 – 4) versus DMSO treatments (lanes 5 – 
7) during TAF6 induction by SSOs TAF6 (right) or in control DMSO treated 
cells (left). The darkness of lane 8 reflects decreasing P-values. (B) A Venn 
diagram indicates a subset of TAF6-regulated genes (491). The black circle 
indicates 375 genes regulated by TAF6 in the absence of GSI while the inner 
red circle indicates the subset of 116 genes whose regulation remains statistically 
 
 
52 
52 
significant (P <0.05) in the presence of GSI. (C) Global impact of GSI on 
TAF6-regulated transcription. Fold change (Y-axis) was normalized with 
microarray data obtained from GSI-free experiments. A value of 1 represents no 
impact of the inhibitor on gene expression. The x-axis represents the 491 TAF6-
regulated ordered by the magnitude of the effect of the GSI from negative (red) 
to positive (green). (D) Gene ontology analysis of the 375 genes whose 
regulation by TAF6 is dampened by inhibiting Notch signalling with GSI. 
Enriched pathways are shown, as are their associated P-values. 
 
We further interrogated the TAF6δ-regulated genes whose induction was reduced by GSI.  
Of the 375 TAF6δ-regulated genes whose changes are dampened by inhibiting Notch 
signalling with GSI several classical Notch target genes were found including Hes1, Cyclin 
D1 and Dusp6 (Figure 20). Since our laboratory has recently shown that the mitochondrial 
BH3-only proteins Noxa and Bim are downstream effectors of TAF6δ-induced apoptosis 
(Delannoy et al., in preparation), we examined their expression in the data set. As expected, 
both the Noxa and Bim transcripts were induced by TAF6δ (Figure 20). The treatment with 
GSI of all of these Notch target genes resulted in a statistically significant reduction in their 
induction by TAF6δ (Figure 20), implying that the Notch pathway contributes to their 
increased expression. To provide further evidence that the Notch pathway is activated by 
TAF6δ, we examined the expression other established Notch target genes whose expression 
was induced by TAF6δ. We found that the induction of both the Notch target genes Hey1 
(Maier and Gessler 2000) and Gata2 (Robert-Moreno et al. 2005) were statistically 
significantly reduced by GSI treatment (Figure 20). To control for specificity we also 
included two TAF6δ-regulated genes, Znf503 and Sesn2, whose expression was not reduced 
by GSI treatment (Figure 20). Taken together, our transcriptome analysis shows that 
inhibition of the Notch signalling pathway significantly dampens the induction a subset of 
TAF6δ-dependent genes that includes five previously identified direct Notch target genes.   
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Figure. 20. TAF6-regulated transcription of Notch target genes. HeLa cells 
treated with GSI were transfected with SSO control or SSO TAF6δ, 18h post-
transfection, RNA was extracted, and microarray analysis was performed. The 
fold induction, as measured by microarray analysis, of known Notch target genes 
and pro-apoptotic genes by TAF6 is shown in the absence (black) and presence 
(red) of GSI (S2188). P <0.05*. 
 
4.1.2 Effect of TAF6δ induction on genes of the Notch pathway at mRNA levels 
 
To further validate and extend the analysis of the impact of TAF6δ on mRNA expression of 
genes from the Notch pathway, we performed qPCR on select genes from the Notch pathway 
in response to endogenous TAF6δ expression. qPCR experiments confirmed the induction of 
the classical Notch target genes Hes1 and Hey2 (Figure 21). We also examined the levels of 
the Notch ligands and found that Dll4 (Delta-like 4) was statistically significantly induced 
(Figure 21). The mRNAs of other ligands including Jag1, Jag2, Dll1 and Dll3 appeared to 
increase as well, though these changes did not reach statistical significance (Figure 21). We 
were particularly interested in the levels of the Notch receptors to obtain insight into possible 
mechanisms of Notch activation in response to TAF6δ. We found that Notch1 and Notch3 
mRNAs were expressed at levels too low in HeLa cells to obtain reproducible quantitation 
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(Figure 21). In contrast, the mRNAs encoding Notch2 and Notch4 receptors were detectable 
(Figure 21). Interestingly, expression of the Notch2 mRNA was modestly but statistically 
significantly induced by TAF6δ (Figure 21). The qPCR confirm TAF6δ-dependent induction 
of several genes in the Notch pathway including the Dll4 ligand and Notch2. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21. Effect of TAF6δ induction on Notch target genes at mRNA levels 
in HeLa cells. The expression of genes from the Notch pathway after 24h 
(except Dll4; 18h) transfection of SSOs, analysed by quantitative RT-PCR. 
Expression of hRPLPO was used as internal control and to normalize the RT-
PCR data. The bars correspond to the ratio SSOs TAF6δ/ SSOs control. Data 
analysed by Student’s t-test, P <0.05*. Error bars indicate the standard deviation 
of three independent experiments. 
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4.1.3 Effect of GSI on Notch pathway at mRNA levels after TAF6δ induction  
 
We next tested the role of the Notch pathway in the TAF6δ-dependent transcriptional 
activation by employing GSI and qPCR to quantify mRNA levels. As seen with earlier 
microarray experiments, the expression of the Notch gene Hes1 was induced by TAF6δ and 
this induction was reduced in the presence of GSI (Figure 22). The induction of the Notch 
ligand Dll4 and the pro-apoptotic effector gene Bim by TAF6δ were also statistically 
significantly reduced (Figure 22). Reductions in Hey2 and Notch2 induction by TAF6δ were 
modest and were not statistically significant (Figure 22). Finally we tested a TAF6δ-
dependent gene Acrc (Wilhelm et al. 2008) to control for the specificity of GSI treatment, 
since its expression was not reduced by GSI treatment (Figure 22). Overall, both the 
microarray experiments and our targeted qPCR revealed a selective set of TAF6δ-dependent 
genes whose induction is reduced by GSI treatment. The data suggest that Notch pathway 
activation can contribute to and shape the TAF6δ-triggered transcriptome landscape.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Effect of GSI on Notch target genes mRNA levels after TAF6δ 
induction in HeLa cells. Inhibition of the Notch genes expression after 18h 
(Hes1, Bim and Acrc) and 24h (Hey2, Dll4 and Notch2) treatment with 50μM 
of the GSI (DAPT) or DMSO as control for 1h before SSOs transfection, 
analysed by quantitative RT-PCR. Expression of hRPLPO was used as internal 
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control and to normalize the RT-PCR data. The y-axis represents the ratio of 
expression in SSOs TAF6δ treated cells versus SSOs control treated cells. Data 
analysed by Student’s t-test, P <0.05*. Error bars indicate the standard deviation 
of three independent experiments. 
 
 
4.2 Objective 2: Determine if TAF6δ affect Notch target genes expression in other cancer 
cell lines. 
 
4.2.1 Effect of TAF6δ induction on Notch pathway genes in pancreatic and breast 
cancer cell lines 
 
We next asked whether or not the activation of genes in the Notch pathway by TAF6δ occurs 
in cancer cells of other origins. In addition to HeLa cervical carcinoma cells, we induced 
endogenous TAF6δ expressing in pancreatic (Panc-1) cell line and two breast cancer cell 
lines (MDA-MB-231 and Hs-578-T) via transfection with SSOs. We surveyed genes within 
the Notch pathway by qPCR and found that indeed several Notch genes were induced in all 
three-cancer cell lines. Although certain genes were induced in a cell type specific fashion 
(for example Hey2, Figure 23), several genes were induced in all cell types tested including 
Hes1, Dll4, Notch2 and Bim (Figure 23). To control for the specificity of TAF6δ-induced 
gene expression we measured transcripts from the Hmox1 gene that displayed reduced or 
unaffected levels (Figure 23). In summary, the data show that the induction of Notch-related 
genes, including Hes1, Dll4, and Notch2, by TAF6δ is a general feature across several cancer 
cell types.  
 
 
 
 
 
 
 
 
 
 
 
57 
57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Effect of TAF6δ induction on Notch target genes at mRNA levels 
in different cancer cell lines. Notch ligands, receptors and target gene 
expression after 24h (except MDA 27h) transfection of SSOs, analyzed by 
quantitative RT-PCR. Expression of hRPLPO was used as an internal control 
and to normalize the RT-PCR data. The y-axis represents the ratio of expression 
in SSOs TAF6δ treated cells versus SSOs control treated cells. Data analysed by 
Student´s t-test, P <0.05*. Error bars indicate the standard deviation of three 
independent experiments. 
 
 
4.3 Objective 3: Test whether there is activation of the Notch pathway in response to 
TAF6δ in HeLa cells. 
 
4.3.1 Effect of GSI on Hes1 protein levels after TAF6δ induction  
 
The above microarray and qPCR analysis showed a γ-secretase-dependent induction of 
Notch target genes including Hes1 in response to TAF6δ at the mRNA level. To test if TAF6δ 
also increases the well-established Notch target Hes1 at the protein level, we used Western 
blot analyses to measure the expression of Hes1 protein in HeLa cells treated. We also tested 
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the requirement for Notch receptor cleavage by using GSI treatment. SSOs were transfected 
to induce TAF6δ expression followed by protein extraction and Western blot analysis. 
Western analysis with antibodies directed against Hes1 (Zhang et al. 2014) showed that the 
protein level of Hes1 was induced in response to TAF6δ (Figure 24A, lane 2 versus lane 1). 
Moreover, treatment with the GSI (DAPT), significantly decreased Hes1 induction by TAF6δ 
(Figure 24A & B). These findings show that the expression of a Notch pathway canonical 
target (Hes1) is affected by TAF6δ induction at the protein as well the mRNA level, and that 
this induction depends on γ-secretase activity. These results provide further support for the 
hypothesis that TAF6δ expression leads to the activation of the Notch signalling pathway. 
 
 
 (A) 
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 (B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Effect of GSI on Hes1 protein levels after TAF6δ induction in 
HeLa cells. Inhibition of Hes1 protein expression after 24h treatment with 50μM 
of the GSI (DAPT) or DMSO as control for 1h before SSOs transfection, 
analysed by Western blot assays (A) Westerns blots were performed using an 
antibody against Hes1 (AB5702, Millipore; 1:2000), or TBP as a loading control. 
(B) Densitometry analysis of the bands corresponding to the ~37kDa Hes1 
signal. Bands were quantified by ImageJ software. The values were normalized 
to TBP, the y-axis represents the ratio of protein expression in cells expressing 
TAF6δ versus control cells.  Data were analysed by the Student’s t-test, P <0.05 
*. Error bars indicate the standard deviation of three independent experiments. 
 
4.3.2 Effect of GSI and EGTA on NIC-1 levels  
 
Cleavage of the Notch receptors by γ-secretase is the crucial biochemical event leading to 
activation of the Notch receptor and its translocation to the nucleus. Notch1 is the best studied 
of the four receptors expressed in human cells. We took advantage of antibodies that 
specifically recognize the cleaved Notch1 intracellular domain (NIC-1) (Takam Kamga et al. 
2016, Wang et al. 2016) to directly test whether the Notch1 receptor is activated in cells 
where TAF6δ expression is induced. Following SSOs induction of TAF6δ, we performed 
Western blot analysis with NIC-1 antibodies. No NIC-1 was detected in control HeLa cells 
(Figure 25, lane 1). Since we had previously shown that HeLa cells express only low levels 
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of Notch1 mRNA, we used the treatment with EGTA that induces Notch cleavage by 
chelating calcium. EGTA resulted in increased NIC-1 detection (Figure 25, lane 4 versus 
lane 2) and this increase was inhibited by GSI treatment (Figure 25, lane 5 versus lane 4). 
These results establish that the NIC-1 antibody can effectively detect cleaved NIC-1 from 
HeLa cell extracts. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Effect of GSI and EGTA on the intracellular active domain of 
Notch1 (NIC-1) in HeLa cells. NIC-1 levels were analysed by Western blot 
with a specific antibody against the intracellular active domain NIC-1 (Cell 
Signalling D3B8, 1:1000), after 24h of treatment with 50µM of GSI (DAPT) or 
DMSO as control and 15 min treatment with EGTA followed by 1h recovery 
period. TBP was used as a loading control. 
 
4.3.3 Effect of SSOs and EGTA on NIC-1 levels  
 
To test the impact of TAF6δ induction on Notch1 activation, we transfected SSOs and 
followed cleaved NIC-1 levels by Western blot analysis. No detectable cleavage of Notch1 
to yield NIC-1 in response to TAF6δ could be observed (Figure 26, lane 2). To ensure that 
the lack of NIC-1 was not due to the limits of detection of the antibody, we induced Notch1 
cleavage to NIC-1 with EGTA treatment and again analyzed NIC-1 levels. EGTA treatment 
resulted in readily detectable NIC-1 (Figure 26, lane 3 versus lane 1), but these induced NIC-
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1 levels were not further increased by the induction of TAF6δ (Figure 26, lane 4 versus lane 
3). We conclude that Notch1 is not significantly activated in response to TAF6δ. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Effect of SSOs and EGTA on the intracellular active domain of 
Notch1 (NIC-1) in HeLa cells. Induction of NIC-1 was analysed by Western 
blot with a specific antibody against the intracellular active domain NIC-1 (Cell 
Signalling D3B8, 1:1000), after 24 h of transfection with SSOs and 15 min 
treatment with EGTA followed by 1h recovery period. TBP was used as a 
loading control. 
 
 
4.3.4 Effect of TAF6δ induction on NIC-2 levels 
 
Since we did not detect cleavage and activation of Notch1, we considered other Notch 
receptors as candidates for activation by TAF6δ. Notch2 was considered a promising 
candidate because, of the four Notch receptors, its mRNA is expressed at the highest levels 
in HeLa cells (Figure 21). More importantly, the Notch2 mRNA is induced in response to 
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TAF6δ (Figure 21). We used a monoclonal antibody that specifically recognizes the 
transmembrane/intracellular region, including the cleaved intracellular form of Notch2, NIC-
2 (Gomi et al. 2015). NIC-2 has a diagnostic molecular weight of ~110 kDa, readily 
distinguishable from the full-length ~265 kDa Notch2 (Blaumueller et al. 1997). Endogenous 
TAF6δ induction via SSO transfection of HeLa cells caused an increase in the levels of NIC-
2 (Figure 27A, lane 2 versus lane 1). Quantification of the results of three independent 
transfections by densitometry showed a statistically significant increase in the levels of NIC-
2 in response to TAF6δ expression (Figure 27B). We conclude that TAF6δ expression in 
HeLa cells increases cleavage and activation of Notch2 to yield NIC-2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
63 
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27. TAF6δ expression increases level of active Notch2 (NIC-2) in 
HeLa cells. Induction of NIC-2 after 18h of transfection with SSOs was 
analyzed by Western blot with an antibody against Notch2 (Cell Signaling 
D67C8, 1:1000) and a band was detected at the expected molecular weight of 
the cleaved fragment of Notch2 (A). (B) Densitometry analysis of the bands 
corresponding to the ~110kDa cleaved NIC-2 fragment. Bands were quantified 
by ImageJ software. The values were normalized to TBP, the y-axis represents 
the ratio of protein expression in cells expressing TAF6δ versus control cells.  
Data analysed by Student’s t-test, P <0.05 *. Error bars indicate the standard 
deviation of three independent experiments. 
 
4.3.5 Effect of TAF6δ induction on cleaved NIC-2 
 
To confirm NIC-2 cleavage as well as to determine whether NIC-2 activation occurs in cells 
expressing TAF6δ, we next performed immunofluorescence on HeLa cells with 
independently developed polyclonal antibodies that specifically recognize cleaved NIC-2 
(Saravanamuthu et al. 2009). Double staining with antibodies directed against cleaved NIC-
2 together with monoclonal antibody against TAF6δ was used to tract the expression of 
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TAF6δ in individual cells. As previously reported (Wilhelm et al. 2008), cells treated with 
TAF6δ-inducing SSOs induced punctate TAF6δ nuclear staining (Figure 28, panel F).  
NIC-2 staining revealed both diffuse nuclear staining and discrete cytoplasmic foci that both 
appeared to increase in response to TAF6δ expression (Figure 28, panel F versus B). We 
interpret the nuclear staining as active (cleaved) chromatin-associated NIC-2 and interpret 
the cytoplasmic foci as active NIC-2 that has been released from the membrane to translocate 
towards the nucleus.  
 
To quantify the immunofluorescence in an unbiased manner, we analyzed the images with 
the CellProfiler 2.1.1 algorithm (Broad Institute, Boston, USA). As expected, SSOs that 
induce TAF6δ expression resulted in a strong induction of the TAF6δ nuclear 
immunofluorescence signal (Figure 28, panel J). Quantification of the NIC-2 signal in 
cytoplasmic foci showed a statistically significant increase in the amount of cytoplasmic 
NIC-2 staining in response to TAF6δ (Figure 28, panel I). We quantified total nuclear NIC-
2 staining as a measure of active NIC-2. TAF6δ-induction caused a statistically significant 
increase in nuclear NIC-2 signal (Figure 28; panel K). To further define the source of 
increased nuclear NIC-2 we calculated the percentage of increased signal (after removal of 
the background signal from control SSOs treated cells) found in TAF6δ positive versus 
TAF6δ negative cells. Interestingly, the majority (55%) of increased NIC-2 signal came from 
cells expressing TAF6δ (Figure 28, panel K), but a substantial portion of the increased signal 
also came from cells with no detectable TAF6δ (Figure 28; panel K). Taken in summary, the 
immunofluorescence data provide an independent confirmation that TAF6δ expression 
causes an increase in nuclear NIC-2, and further show that this increase occurs both TAF6δ-
expressing and neighbouring cells. The results support a model wherein TAF6δ increases 
NIC-2 via intracellular signalling, but also via cell-cell signalling via the Notch pathway.
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Figure 28. TAF6δ-expression increases level of active nuclear Notch2 (NIC-
2) in HeLa cells. Induction of NIC-2 was analyzed by immunofluorescence with 
a specific antibody against the intracellular active domain NIC-2 (Abcam 8926, 
1:1000), after 18h of transfection with SSOs (40x magnification in all panels). 
HeLa cells were treated with SSOs Control, panels (A-D) vs SSOs TAF6δ, 
panels (E-H). Panels (A and E) show nuclear staining with Hoechst. Panels (B 
and F), represent nuclear fluorescence of NIC-2, where two cells are indicated 
(rectangle). Panels (C and G) show TAF6δ expressing cells (nuclear orange 
foci), where two cells are indicated (rectangle). Panels (D and H) show the merge 
of the green and orange channels with the nucleus. (I) Quantitation of total green 
foci (Transit NIC-2 signal) counted divided by the total number of cells. (J) 
Quantitation of the percentage of TAF6δ induction calculated based on the 
number of cells with punctate TAF6δ staining/total number of cells. (K) 
Quantitation of the total nuclear fluorescence of NIC-2. The 
immunofluorescence was analyzed for at least 300 cells for each condition 
(SSOs Control and SSOs TAF6δ). Quantifications were performed by 
CellProfiler 2.1.1 software, P ≤0.01. Error bars indicate the standard deviation 
of four independent experiments. 
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B) General Objective  
Can Notch activation contribute to TAF6δ-dependent apoptosis? 
 
4.4 Objective 4: Determine the effect of inhibiting the Notch pathway on TAF6δ- induced 
apoptosis in HeLa cells. 
 
4.4.1 Effect of GSI on apoptosis 
 
Given that TAF6δ can induce Notch signalling via the activation of Notch2, we next tested 
the physiological impact of Notch signalling on TAF6δ-dependent cell death. We initially 
tested the effect of GSI (DAPT) treatment on apoptosis in normal culture conditions. 
Apoptosis was followed by flow cytometry using antibodies directed against activated 
Caspase-3. GSI treatment had no significant effect on the apoptosis observed under standard 
culture conditions of HeLa cells (Figure 29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. GSI does not affect apoptosis in HeLa Cells, as measured by flow 
cytometry. Cells were treated with GSI (DAPT) for 24h. The percentage of 
apoptotic cells was analysed by flow cytometry using a monoclonal antibody 
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that detects cleaved caspase 3. Error bars indicate the standard deviation of three 
independent experiments. 
 
4.4.2 Effect of GSI on Cisplatin induced apoptosis 
 
To further exclude the possibility of non-specific effects of GSI (DAPT) treatment in HeLa 
cells, we measured its impact on HeLa cells treated with the chemotherapeutic agent 
cisplatin. As before, we analyzed apoptosis by flow cytometry with antibodies against active 
Caspase-3. GSI caused no reduction in cisplatin-induced cell death at either of two 
concentrations used (Figure 30). We conclude that GSI does not non-selectively reduce 
apoptosis in HeLa cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. HeLa Cells in the presence of GSI and two doses of Cisplatin 
apoptosis-inductor. Cells were treated with 50μM of the GSI (DAPT) or 
DMSO as control for 1h, following by treatment with two doses of Cisplatin 
(25μM and 50μM) for 16h. The percentage of apoptotic cells was analysed by 
flow cytometry using a monoclonal antibody that detects cleaved caspase 3. 
Error bars indicate the standard deviation of three independent experiments. 
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4.4.3 Down-regulation of Notch signalling by GSI treatment reduces apoptotic effects 
of TAF6δ 
 
We next investigated whether inhibition of Notch signalling by GSI treatment resulted in a 
significant reduction of apoptosis induce by TAF6δ expression in HeLa cells. We again 
performed flow cytometry to measure apoptosis by staining for cleaved caspase-3 (Neradil 
et al. 2015), a key protease in the execution of the apoptosis process (Riedl and Shi 2004, 
Parrish et al. 2013). GSI treatment caused a statistically significant drop in the levels of 
apoptosis induced by TAF6δ induction (Figure 31). These data demonstrate a specific 
reduction of TAF6δ induced apoptosis in presence of GSI, showing that Notch signalling 
contributes significantly to TAF6δ-driven apoptosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 31. GSI reduces apoptotic effects of TAF6δ induction in HeLa Cells, 
as measured by flow cytometry. Cells were treated with 50μM of the GSI 
(DAPT) or DMSO as control for 1h, following by transfection of SSOs. Twenty-
four hours later, the percentage of apoptotic cells was analysed by flow 
cytometry using monoclonal antibody that detects the functional cleaved caspase 
3. The y-axis represents the ratio of apoptosis in SSOs TAF6δ treated cells versus 
SSOs control treated cells. Data analysed by Student’s t-test, P <0.05*. Error 
bars indicate the standard deviation of three independent experiments. 
TAF6δ dependent Apoptosis 
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5 DISCUSSION AND 
CONCLUSION 
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The Notch signalling pathway regulates several cellular processes, including cell 
differentiation, proliferation, and apoptosis. In mammalians, this pathway involves a group 
of Notch ligands (Delta-like and Jagged families) and Notch receptors (Notch 1-4) whose 
intracellular domain is translocated to the nucleus upon activation through cleavage by the γ-
secretase complex. Once in the nucleus, the intracellular active domain (NIC) interacts with 
the CSL protein, activating the transcriptional complex that includes co-activators such as 
MAML1 and p300. Subsequently, it regulates the transcription of its Notch target genes: 
Hes1, Cyclin D1 and others (Table 5) (Kopan and Ilagan 2009, Andersson et al. 2011, 
Ranganathan et al. 2011, Schwanbeck et al. 2011, Wang 2011).  
 
The TAF6δ pathway induces apoptosis (Wilhelm et al. 2008) and has also been implicated 
in the regulation of other pathways such as integrin, oxidative stress, angiogenesis and Notch 
(Wilhelm et al. 2010). However, the precise physiological context of TAF6δ-dependent cell 
death and the underlying molecular mechanisms remains unknown. In our previous study 
(Wilhelm et al. 2010), we found that endogenous TAF6δ induction has an impact on gene 
expression, including the induction of classic Notch target genes like Hes1, with the most 
significant P-value. By defining a mechanistic link between the Notch and TAF6δ signalling 
pathways, we hoped to acquire further knowledge into the specific physiological role of 
TAF6δ. 
 
To test the hypothesis that TAF6δ activates Notch signalling and whether the Notch pathway 
participates in apoptosis induction, additional studies were needed. In this study, we 
investigated the association between TAF6δ and Notch pathways and their link with 
apoptotic process.  
  
The goal of my master’s work was, therefore, to answer two questions. Firstly, does TAF6δ 
expression cause activation of the Notch pathway? Secondly, can Notch activation contribute 
to TAF6δ-dependent apoptosis? 
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In order to answer the first question our first specific objective was to analyze the expression 
of Notch target genes in the presence and absence of GSI (γ-secretase inhibitor) after TAF6δ 
expression in HeLa cells. Our earlier results indicated that TAF6δ induction produces an 
increase in the expression of Notch target genes (Wilhelm et al. 2010). To verify whether 
inhibition of the Notch pathway with GSI (that prevents cleavage of full-length Notch to 
yield the active intracellular domain of Notch, NIC (Tolia and De Strooper 2009, Groth and 
Fortini 2012, Olsauskas-Kuprys et al. 2013)), affects gene expression in the presence of 
TAF6δ, we performed a microarray analysis that revealed that the GSI treatment selectively 
reduced TAF6δ-dependent induction of gene expression. We also observed that the analysis 
showed a significant decrease in the TAF6δ-dependent induction genes, including direct 
Notch down-stream target genes such as Hes1, Cyclin D1 and Dusp6 (Figure 19).  
 
In addition, pro-apoptotic genes activated by TAF6δ like Bim and Noxa, which play an 
important role in apoptosis mediated by the intrinsic pathway (Ploner et al. 2008, Faber et al. 
2012, Zhang et al. 2013). Bim, as a BH3-only protein is classified as an activator and has 
been implicated in the regulation of cell death when cells receive stimulus with growth 
factors and other stimuli like matrix detachment, cytokine deprivation, glucocorticoids and 
calcium deprivation. Moreover, Bim leads to apoptosis through the intrinsic pathway by 
activating Bax and Bak proteins (Sionov et al. 2015, Deng 2017). In addition, Noxa is also a 
BH3-only protein that is classified as a sensitizer due to its weak pro-apoptotic activity. 
Therefore, Noxa requires an partnership with other BH3-only members to be able to promote 
cell death (Albert et al. 2014).  
 
In our microarray analysis, increased gene expression of Bim and Noxa; mediated by TAF6δ 
induction has also been shown to be prevented by Notch pathway inhibition (Figure 20). Our 
group has recently demonstrated that Bim and Noxa are effectors of TAF6δ (Delannoy et al., 
in preparation), therefore, one mechanism by which the Notch pathway may contribute to 
TAF6δ-driven apoptosis is by enhancing the expression of these pro-apoptotic genes. We 
also observed two genes that are not related to Notch pathway, Znf503 and Sesn2 in which 
the effect is different in presence of GSI. These results reinforce the selectivity of γ-secretase 
inhibitors, showing that only a subset of genes have been downregulated after blocking the 
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Notch pathway. These results are consistent with a role of the Notch pathway in the induction 
of TAF6δ-dependent apoptosis (Yang et al. 2004). We selected a group of genes and 
confirmed their regulation by qPCR experiments. First, we validated that genes belonging to 
the Notch signalling pathway were induced by TAF6δ, and indeed that Notch target genes, 
Notch ligands and specifically one Notch receptor (Notch2), displayed an increased 
expression in presence of TAF6δ (Figure 21). Subsequently, we tested the effect of inhibiting 
the Notch pathway with GSI in presence of TAF6δ. It was observed that the induction of 
Notch target genes as Hes1, Notch Ligands as Dll4, Notch2, and pro-apoptotic genes as Bim 
were reduced when the Notch pathway was blocked concomitantly TAF6δ induction with a 
significant P-value, P <0.05 in HeLa cells (Figure 22). Hence, these results corroborate our 
microarray data and suggest a link between TAF6δ and Notch pathways in HeLa cells. 
 
Our second specific objective was to determine if TAF6δ affects Notch target gene 
expression in other cancer cell lines. We found that TAF6δ expression is able to up-regulate 
various Notch target genes, Notch ligands mostly Delta-like family, Notch receptors and pro-
apoptotic genes in pancreatic (Panc-1) and breast (MDA-MB-231 and Hs-578-T) cancer cell 
lines as it was shown above with the cervical cancer cell line, HeLa (Figure 23). Therefore, 
the microarray and qPCR data shows that TAF6δ can drive the expression of genes in the 
Notch pathway in several independent cancer cell lines of distinct tissue origins. 
  
After, having shown that a subset of TAF6δ-induced genes is blocked upon Notch pathway 
inhibition (using GSI), we proceeded to determine the level of Notch activation upon TAF6δ 
expression in HeLa cells.  
 
Hes1 is the most well characterized Notch target gene that can regulate cell fate decisions 
(Fischer and Gessler 2007, Ranganathan et al. 2011, Liu et al. 2015). Hes1 functions include 
cell cycle control that create a balance within proliferation and differentiation (Monahan et 
al. 2009) and an important role in development of the nervous system, pancreas and 
lymphocytes (Fischer and Gessler 2007). It has also been published that Hes1 mediates the 
connection between Notch pathway and apoptosis (Nickoloff et al. 2005, Robert-Moreno et 
al. 2007, Konishi et al. 2010, Kannan et al. 2011).  
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In addition to demonstrating increases in Hes1 mRNA levels, we also wanted to know at the 
protein level whether the inhibition of the Notch pathway resulted in decreased expression 
of this classical Notch target gene in response to TAF6δ induction. Indeed, we found that 
TAF6δ-induced Hes1 expression was significantly reduced in GSI presence (Figure 24), 
which strongly suggest that TAF6d induces Hes1 transcription through activation of the 
Notch pathway in HeLa cells.  
 
Furthermore, our study also showed that TAF6δ does not increase the level of the cleaved 
Notch1 intracellular domain (NIC-1). In order to observe NIC-1, EGTA (calcium-chelating) 
was added to induce the cleavage of the Notch 1 (Rand et al. 2000) (Figures 25-26). EGTA 
induces Notch1 cleavage as this receptor is composed of two domains, the extracellular and 
the intracellular, that are held together via non-covalent interactions that depend on calcium. 
Therefore, calcium depletion results in the dissociation of the extracellular and intracellular 
domains so the intracellular domain became more accessible to proteolysis by γ-secretase 
complex (De Strooper et al. 1999, Rand et al. 2000). Given that TAF6δ did not lead to 
increased NIC-1 expression, this result suggested an activation of the Notch pathway by 
TAF6δ through another receptor, like Notch2. Increased cleavage of Notch2, the only 
receptor upregulated by TAF6δ, was increased upon TAF6δ expression as measured by 
western blot and qPCR (Figure 27). This result suggests a direct activation of the Notch 
signalling pathway by TAF6δ expression through the Notch2 in HeLa cells. We did not test 
Notch3 and Notch4 receptors in HeLa cells. Due to the qPCR results revealed that Notch3 
levels were too low to be able to detect and Notch4 were not significantly affected by TAF6δ. 
The demonstration of Notch2 cleavage in response to TAF6δ provides the first mechanistic 
information underlying the functional link between the TAF6δ and Notch pathways. 
 
In order to confirm whether TAF6δ activates the Notch2, nuclear NIC-2 levels were 
measured after TAF6δ induction (Figure 28). Immunofluorescence analysis showed good 
transfection efficiency, with 53% of cells induced to express TAF6δ (P-value, P <0.05). The 
analysis also showed that total NIC-2 nuclear fluorescence increased in TAF6δ presence with 
a statistical P-value, P <0.05 and the contribution of this fluorescence came mainly from cells 
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expressing TAF6δ with 55%, implying that Notch2 activation leading to NIC-2 nuclear 
localization occurs in TAF6δ–expressing cells. 
  
Nevertheless, there was a contribution (45%) from cells not expressing TAF6δ. These data 
are consistent with a model wherein both intracellular signalling, via transcriptional crosstalk 
between Notch2 and TAF6δ, and extracellular signalling, via Notch ligand induction, 
contribute to enhance apoptosis. This model is further supported by our microarray, qPCR 
and western blot experiments that demonstrated the induction of both Notch2 cleavage and 
increased Notch ligand expression (eg. Dll4) in cell populations where endogenous TAF6δ 
is enforced. Activation of Notch2 has been reported through ligand-expressing cells (Dll1-4 
and Jagged1-2) by co-culture or recombinant Dll4 that also required a proteolytic cleavage 
through Adam10 metalloprotease and γ-secretase complex to allow transcriptional activation 
of the Notch target genes (Groot et al. 2014). The physical binding of the Notch ligands 
(Delta-like and Jagged1-2) to the endogenous Notch2, with higher affinity for the Delta 
family (eg. Dll1) had been validated by a cell-cell association assay. This Dll1-Notch2 
association, in order induces cleavage and nuclear translocation of NIC-2 (Shimizu et al. 
2000).  
 
Moreover, another parameter evaluated was total NIC-2-specific fluorescence foci in the 
cytoplasm in the presence and absence of TAF6δ. Our interpretation of these foci is that they 
represent NIC-2 in transit, while active NIC-2 is translocated from the cytoplasm to the 
nucleus. The measures revealed that when TAF6δ is induced, we counted more NIC-2-
specific foci in the cytoplasm. We interpret the results as implying that in presence of TAF6δ 
there is more active NIC-2 in transit to the nucleus. Our results also confirmed by 
immunofluorescence that the expression of TAF6δ induces an increased the active Notch2 
within the nucleus. 
 
These results suggest that cell to cell communication contribute to Notch activation in 
neighboring cells, a model that is consistent with the well-established role of Notch signalling  
between cells (Kato 2011). Cellular communication studies showed that the Lunatic fringe 
protein (Lfng) is able to potentiate both ligands Jagged1 and Delta-like1 signalling towards 
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Notch2 (Hicks et al. 2000) but inhibits Jagged1 and potentiates Delta-like1 signalling through 
Notch1. These reports suggest that Lfng modulates the interactions between Notch ligands 
and Notch receptors, indicating that there is a positive feedback loop from cell-to-cell to 
generate signal propagation (Hicks et al. 2000, Matsuda et al. 2012). In fact, another study 
demonstrated that endothelial cells communicate with mural cells in order to regulate vessel 
assembly and differentiation through Notch3 activation by a positive-feedback loop that 
includes autoregulation and Jagged expression (Liu et al. 2009). 
 
To determine whether Notch activation can contribute to TAF6δ-dependent apoptosis, our 
fourth specific objective was to determine the effect of inhibiting the Notch pathway on 
TAF6δ-induced apoptosis in HeLa cells. It has been reported that the activation of the Notch 
pathway is capable of contributing to the induction of apoptosis, such as tumor suppressor 
(Chadwick et al. 2008, Jiao et al. 2009, Nowell and Radtke 2017). Indeed, it has been shown 
that overexpression of Notch1 leads to inhibition of proliferation followed by apoptosis 
through up-regulation of p21 (promotes cell cycle arrest) (Nowell and Radtke 2017), IFI 16 
(inhibit cell cycle and induce apoptosis) (Chadwick et al. 2008), caspases 3, 9 and down-
regulation of cyclin E, Cdk2 and bcl-2 (Jiao et al. 2009). In addition, ablation of Notch 
activity through deletion of Notch1 and Notch2 or CSL increased tumor development, 
indicating that Notch can act in an anti-tumorigenic manner (Nowell and Radtke 2017). 
Another contribution to this network between the Notch and apoptosis pathways comes from 
the most studied gene of the Notch signalling, Hes1. The functions described to contribute to 
the ability of Hes1 to induce apoptosis include: its association with PARP1 protein (Kannan 
et al. 2011), negative regulation of the anti-apoptotic proteins of the Bcl-2 family (Robert-
Moreno et al. 2007) and the induction of the pro-apoptotic BH3-only proteins, Bim and Noxa 
(Nickoloff et al. 2005, Konishi et al. 2010). 
 
To test a role of Notch signalling in TAF6δ-dependent apoptosis, we initially tested whether 
GSI could non-specifically affect the percentage of apoptosis. Flow cytometry measures did 
not reveal significant differences in the percentage of apoptosis between treatment with GSI 
and DMSO (inhibitor vehicle) in HeLa cells under standard growth conditions (Figure 29). 
Subsequently, a positive inducer of apoptosis, cisplatin, was tested in combination with GSI, 
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but no significant differences were observed between percentages of apoptosis induce with 
DMSO vs GSI (Figure 30). Having determined that the GSI did non-selectively reduce 
apoptosis, we wanted to test the effect of GSI specifically on TAF6δ-mediated cell death. 
We asked if down-regulation of the Notch pathway could result in a reduction of apoptosis 
induction by TAF6δ. The results revealed that down-regulation of Notch signalling reduced 
TAF6δ-dependent apoptosis levels by 17% (Figure 31). This suggests that Notch pathway 
activation by TAF6δ positively influences the apoptotic cascade. This result, to my 
knowledge, is the first example of reciprocal feedback between the Notch pathway and 
apoptosis. In other words, pro-apoptotic TAF6δ activates Notch signalling, that in turn 
contributes to the process of apoptosis. Based on the direct link between Notch target genes 
expression and TAF6δ, we propose a model in which activation of the Notch pathway by 
TAF6δ is essential for initiating TAF6δ-mediated apoptotic process (Figure 32). 
 
Further work will be required to determinate which specific molecular mechanisms TAF6δ 
exploits to induce Notch pathway activation. One hypothesis could be that TAF6δ could 
induce the expression of one of the Notch ligands in order to activate the Notch receptor as 
reported in the literature (Wang 2011), like Delta-like four (Dll4), for example. Dll4 has been 
associated with cervical cancer (Yang et al. 2016) and was induced in all the cancer cell lines 
that we tested (Figure 21 and 23). Therefore, we propose a crosstalk model that shows an 
activation of the Notch signalling pathway through Delta-like four ligand by TAF6δ and its 
association contributes to apoptosis in HeLa cells (Figure 33). 
 
Another possibility could be an association between TAF6δ and the γ-secretase complex, 
(which increases Notch intracellular domain release by the γ-secretase cleavage (Jurisch-
Yaksi et al. 2013)) based on our microarray data that showing increased expression in some 
subunits of this complex, like Aph1b (Anterior pharynx-defective 1) and Pen2/Psenen 
(Presenilin Enhancer 2). However, to validate this hypothesis, additional studies will be 
needed. Indeed, the characterization of the complete molecular mechanism through which 
TAF6δ activates the Notch pathway should provide a better understanding the complex 
interplay between TAF6δ and cell death, particularly in the context of tumor biology. 
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In terms of perspectives, it would be interesting to study whether other cancer cell lines where 
TAF6δ induces apoptosis use the same molecular mechanism found in HeLa cells, in which 
TAF6δ, the Notch signalling pathway and the apoptosis process are associated. In addition, 
it will be important to confirm activation of the intracellular domain of Notch2 (NIC-2) and 
the cellular localization of NIC-2, in the absence and presence of GSI after TAF6δ expression 
in HeLa cells. Another parameter to evaluate could be to verify whether TAF6δ regulates the 
expression of the different subunits of the gamma-secretase complex. To confirm the 
involvement of Notch2 activation in the TAF6δ-induced effect, it would be mandatory to 
assess the impact of knocking down Notch2 in TAF6δ-expressing cells. As well, it should be 
fascinating to analyze in a physiological context whether TAF6δ-Notch crosstalk interacts 
functionally with other pathways that were statistically over-represented after TAF6δ 
induction in microarray analysis, such as hypoxia or angiogenesis (Wilhelm et al. 2010). It 
has been reported in the literature a link between Notch and hypoxia pathways through the 
regulation of Notch ligands, Notch receptors or the transcriptional activation of Notch 
downstream target genes such as Hes1 (Lee et al. 2009, Borggrefe et al. 2016). The first 
molecular mechanism of action that were proposed elucidated an up-regulation of the Notch 
ligand, Dll4 by hypoxia in a HIF-1α-dependent manner (Borggrefe et al. 2016). In addition, 
the Notch pathway has been implicated as an important regulator of angiogenesis. Notch 
signalling is able to regulate the differentiation of endothelial cells and blood vessels, but 
defects in Notch can lead to inhibition on network formation of the endothelial cells and 
vessel-like structures in angiogenesis, and also lead to cardiovascular diseases (Liu et al. 
2003, Gridley 2007). 
 
In summary, the results presented here demonstrate that inhibition of the Notch pathway 
reduces the TAF6δ-dependent induction of Notch ligand (Dll4) and Notch target genes. In 
addition, several Notch target genes, Notch ligands and Notch receptors are upregulated by 
TAF6δ expression in different cancer cell lines. Furthermore, TAF6δ activates the Notch 
signalling pathway through cleavage of the Notch2 and is involved in the induction of 
apoptosis in HeLa cervical cancer cell line. Finally, the data demonstrated that activation of 
the Notch pathway by TAF6δ contributes to TAF6δ-driven apoptosis.  
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Figure 32. First model for crosstalk between the TAF6δ and Notch pathways. A hypothetical model showing the activation of Notch 
pathway by TAF6δ through activation of Notch2 (see text for details). 
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Figure 33. Second model for crosstalk between the TAF6δ and Notch pathways. A hypothetical model showing the activation of 
Notch pathway by TAF6δ through activation of Notch ligand, Dll4 (please see text for details). 
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Attachment 2  
 
Table 5. Notch Signalling Pathway Target Genes 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cellular Process Notch Target Genes 
Apoptosis CDKN1A, CFLAR (CASH), IL2RA, 
NFKB1 
Cell Cycle Regulators CCND1, CDKN1A, IL2RA 
Cell Proliferation CDKN1A, ERBB2, FOSL1, IL2RA 
Cell Differentiation Regulators DTX1, PPARG 
Neurogenesis HES1, HEY1 
Regulation on Transcription DTX1, FOS, FOSL1, HES1, HEY1, 
NFKB1, NFKB2, NR4A2, PPARG, STAT6 
Other Target Genes with Unspecified 
Functions 
CD44, CHUK, IFNG, IL17B, KRT1, LOR, 
MAP2K7, PDPK1, PTCRA. CCND1, 
CDKN1A, GATA3 and PTCRA 
 
 
83 
83 
LIST OF REFERENCES 
Adams, J. M. and S. Cory (2007). "Bcl-2-regulated apoptosis: mechanism and therapeutic 
potential." Curr Opin Immunol 19(5): 488-496. 
Albert, M. C., K. Brinkmann and H. Kashkar (2014). "Noxa and cancer therapy: Tuning up 
the mitochondrial death machinery in response to chemotherapy." Mol Cell Oncol 1(1): 
e29906. 
Allenspach, E. J., I. Maillard, J. C. Aster and W. S. Pear (2002). "Notch signaling in cancer." 
Cancer biology & therapy 1(5): 466-476. 
Andersson, E. R., R. Sandberg and U. Lendahl (2011). "Notch signaling: simplicity in design, 
versatility in function." Development 138(17): 3593-3612. 
Aoyagi, N. and D. A. Wassarman (2001). "Developmental and transcriptional consequences 
of mutations in Drosophila TAF(II)60." Mol Cell Biol 21(20): 6808-6819. 
Arnoult, D., B. Gaume, M. Karbowski, J. C. Sharpe, F. Cecconi and R. J. Youle (2003). 
"Mitochondrial release of AIF and EndoG requires caspase activation downstream of 
Bax/Bak-mediated permeabilization." EMBO J 22(17): 4385-4399. 
Artavanis-Tsakonas, S., M. D. Rand and R. J. Lake (1999). "Notch signaling: cell fate control 
and signal integration in development." Science 284(5415): 770-776. 
Bauman, J., N. Jearawiriyapaisarn and R. Kole (2009). "Therapeutic potential of splice-
switching oligonucleotides." Oligonucleotides 19(1): 1-13. 
Becavin, C., N. Tchitchek, C. Mintsa-Eya, A. Lesne and A. Benecke (2011). "Improving the 
efficiency of multidimensional scaling in the analysis of high-dimensional data using 
singular value decomposition." Bioinformatics 27(10): 1413-1421. 
Bell, B., E. Scheer and L. Tora (2001). "Identification of hTAF(II)80 delta links apoptotic 
signaling pathways to transcription factor TFIID function." Mol Cell 8(3): 591-600. 
Bhaumik, S. R. (2011). "Distinct regulatory mechanisms of eukaryotic transcriptional 
activation by SAGA and TFIID." Biochim Biophys Acta 1809(2): 97-108. 
Birck, C., O. Poch, C. Romier, M. Ruff, G. Mengus, A. C. Lavigne, I. Davidson and D. Moras 
(1998). "Human TAF(II)28 and TAF(II)18 interact through a histone fold encoded by 
atypical evolutionary conserved motifs also found in the SPT3 family." Cell 94(2): 239-249. 
Blaumueller, C. M., H. Qi, P. Zagouras and S. Artavanis-Tsakonas (1997). "Intracellular 
cleavage of Notch leads to a heterodimeric receptor on the plasma membrane." Cell 90(2): 
281-291. 
 
 
84 
84 
Borggrefe, T., M. Lauth, A. Zwijsen, D. Huylebroeck, F. Oswald and B. D. Giaimo (2016). 
"The Notch intracellular domain integrates signals from Wnt, Hedgehog, TGFbeta/BMP and 
hypoxia pathways." Biochim Biophys Acta 1863(2): 303-313. 
Braun, F., S. de Carne Trecesson, J. Bertin-Ciftci and P. Juin (2013). "Protect and serve: Bcl-
2 proteins as guardians and rulers of cancer cell survival." Cell Cycle 12(18): 2937-2947. 
Bray, S. J. (2016). "Notch signalling in context." Nat Rev Mol Cell Biol 17(11): 722-735. 
Bruce Alberts, A. J., Julian Lewis, Martin Raff, Keith Roberts, and Peter Walte (2002). 
"Programmed Cell Death (Apoptosis)." Molecular Biology of the Cell. 
Cancer, I. A. f. R. o. (2012). "GLOBOCAN 2012: Estimated Cancer Incidence, Mortality 
and Prevalence Worldwide in 2012." 
Cande, C., F. Cecconi, P. Dessen and G. Kroemer (2002). "Apoptosis-inducing factor (AIF): 
key to the conserved caspase-independent pathways of cell death?" J Cell Sci 115(Pt 24): 
4727-4734. 
Chadwick, N., C. Fennessy, M. C. Nostro, M. Baron, G. Brady and A. M. Buckle (2008). 
"Notch induces cell cycle arrest and apoptosis in human erythroleukaemic TF-1 cells." Blood 
Cells Mol Dis 41(3): 270-277. 
Chen, S. M., J. P. Liu, J. X. Zhou, C. Chen, Y. Q. Deng, Y. Wang and Z. Z. Tao (2011). 
"Suppression of the notch signaling pathway by gamma-secretase inhibitor GSI inhibits 
human nasopharyngeal carcinoma cell proliferation." Cancer Lett 306(1): 76-84. 
Choudhury, J. D., S. K.  and V. M. (2012). "A review on apoptosis & its different pathway " 
International Journal of Biological & Pharmaceutical Research 3(7): 848-861. 
Clancy, S. (2008). "DNA Transcription." Nature Education 1(1): 41. 
Cler, E., G. Papai, P. Schultz and I. Davidson (2009). "Recent advances in understanding the 
structure and function of general transcription factor TFIID." Cell Mol Life Sci 66(13): 2123-
2134. 
Coates, J. M., J. M. Galante and R. J. Bold (2010). "Cancer therapy beyond apoptosis: 
autophagy and anoikis as mechanisms of cell death." J Surg Res 164(2): 301-308. 
Contreras-Cornejo, H., G. Saucedo-Correa, J. Oviedo-Boyso, J. J. Valdez-Alarcon, V. M. 
Baizabal-Aguirre, M. Cajero-Juarez and A. Bravo-Patino (2016). "The CSL proteins, 
versatile transcription factors and context dependent corepressors of the notch signaling 
pathway." Cell Div 11: 12. 
Cory, S. and J. M. Adams (2002). "The Bcl2 family: regulators of the cellular life-or-death 
switch." Nat Rev Cancer 2(9): 647-656. 
 
 
85 
85 
Crum, C. P. (2000). "Contemporary theories of cervical carcinogenesis: the virus, the host, 
and the stem cell." Modern pathology: an official journal of the United States and Canadian 
Academy of Pathology, Inc 13(3): 243-251. 
D'Souza, B., A. Miyamoto and G. Weinmaster (2008). "The many facets of Notch ligands." 
Oncogene 27(38): 5148-5167. 
Daniel, B., A. Rangarajan, G. Mukherjee, E. Vallikad and S. Krishna (1997). "The link 
between integration and expression of human papillomavirus type 16 genomes and cellular 
changes in the evolution of cervical intraepithelial neoplastic lesions." The Journal of general 
virology 78 ( Pt 5): 1095-1101. 
Dash, P. (2015). "Role of Apoptosis in Health and Disease." 
De Strooper, B., W. Annaert, P. Cupers, P. Saftig, K. Craessaerts, J. S. Mumm, E. H. 
Schroeter, V. Schrijvers, M. S. Wolfe, W. J. Ray, A. Goate and R. Kopan (1999). "A 
presenilin-1-dependent gamma-secretase-like protease mediates release of Notch 
intracellular domain." Nature 398(6727): 518-522. 
Deng, J. (2017). "How to unleash mitochondrial apoptotic blockades to kill cancers?" Acta 
Pharm Sin B 7(1): 18-26. 
Dexter, J. S. (1914). "The Analysis of a Case of Continuous Variation in Drosophila by a 
Study of Its Linkage Relations." The American Naturalist 48(576): 712-758. 
Dipak D. Ghatage, S. R. G., Sindhu M. Ganvir, Vinay K. Hazarey (2012). "Apoptosis: 
Molecular mechanism." Journal of Orofacial Sciences 4(2): 103-107. 
Dlamini, Z., Z. Mbita and M. Zungu (2004). "Genealogy, expression, and molecular 
mechanisms in apoptosis." Pharmacol Ther 101(1): 1-15. 
Doorbar, J., W. Quint, L. Banks, I. G. Bravo, M. Stoler, T. R. Broker and M. A. Stanley 
(2012). "The biology and life-cycle of human papillomaviruses." Vaccine 30 Suppl 5: F55-
70. 
Dotto, G. P. (2008). "Notch tumor suppressor function." Oncogene 27(38): 5115-5123. 
Dyson, N., P. M. Howley, K. Münger and E. Harlow (1989). "The human papilloma virus-
16 E7 oncoprotein is able to bind to the retinoblastoma gene product." Science (New York, 
N.Y.) 243(4893): 934-937. 
Efferson, C. L., C. T. Winkelmann, C. Ware, T. Sullivan, S. Giampaoli, J. Tammam, S. Patel, 
G. Mesiti, J. F. Reilly, R. E. Gibson, C. Buser, T. Yeatman, D. Coppola, C. Winter, E. A. 
Clark, G. F. Draetta, P. R. Strack and P. K. Majumder (2010). "Downregulation of Notch 
pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin 
signaling and glucose uptake in an ERBB2 transgenic breast cancer model." Cancer Res 
70(6): 2476-2484. 
 
 
86 
86 
Elmore, S. (2007). "Apoptosis: a review of programmed cell death." Toxicol Pathol 35(4): 
495-516. 
Engin, F., T. Bertin, O. Ma, M. M. Jiang, L. Wang, R. E. Sutton, L. A. Donehower and B. 
Lee (2009). "Notch signaling contributes to the pathogenesis of human osteosarcomas." Hum 
Mol Genet 18(8): 1464-1470. 
Faber, A. C., H. Ebi, C. Costa and J. A. Engelman (2012). "Apoptosis in targeted therapy 
responses: the role of BIM." Adv Pharmacol 65: 519-542. 
Ferlay, J., I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. M. Parkin, D. 
Forman and F. Bray (2015). "Cancer incidence and mortality worldwide: sources, methods 
and major patterns in GLOBOCAN 2012." Int J Cancer 136(5): E359-386. 
Fischer, A. and M. Gessler (2007). "Delta-Notch--and then? Protein interactions and 
proposed modes of repression by Hes and Hey bHLH factors." Nucleic Acids Res 35(14): 
4583-4596. 
Fortini, M. E. (2009). "Notch signaling: the core pathway and its posttranslational 
regulation." Developmental cell 16(5): 633-647. 
Fuchs, Y. and H. Steller (2015). "Live to die another way: modes of programmed cell death 
and the signals emanating from dying cells." Nat Rev Mol Cell Biol 16(6): 329-344. 
Gangloff, Y. G., J. C. Pointud, S. Thuault, L. Carre, C. Romier, S. Muratoglu, M. Brand, L. 
Tora, J. L. Couderc and I. Davidson (2001). "The TFIID components human TAF(II)140 and 
Drosophila BIP2 (TAF(II)155) are novel metazoan homologues of yeast TAF(II)47 
containing a histone fold and a PHD finger." Mol Cell Biol 21(15): 5109-5121. 
Gangloff, Y. G., C. Romier, S. Thuault, S. Werten and I. Davidson (2001). "The histone fold 
is a key structural motif of transcription factor TFIID." Trends Biochem Sci 26(4): 250-257. 
Gangloff, Y. G., S. L. Sanders, C. Romier, D. Kirschner, P. A. Weil, L. Tora and I. Davidson 
(2001). "Histone folds mediate selective heterodimerization of yeast TAF(II)25 with TFIID 
components yTAF(II)47 and yTAF(II)65 and with SAGA component ySPT7." Mol Cell Biol 
21(5): 1841-1853. 
Gangloff, Y. G., S. Werten, C. Romier, L. Carre, O. Poch, D. Moras and I. Davidson (2000). 
"The human TFIID components TAF(II)135 and TAF(II)20 and the yeast SAGA components 
ADA1 and TAF(II)68 heterodimerize to form histone-like pairs." Mol Cell Biol 20(1): 340-
351. 
Gewies, A. (2003). "Introduction to Apoptosis." ApoReview: 26. 
Ghittoni, R., R. Accardi, S. Chiocca and M. Tommasino (2015). "Role of human 
papillomaviruses in carcinogenesis." Ecancermedicalscience 9: 526. 
 
 
87 
87 
Goldar, S., M. S. Khaniani, S. M. Derakhshan and B. Baradaran (2015). "Molecular 
mechanisms of apoptosis and roles in cancer development and treatment." Asian Pac J Cancer 
Prev 16(6): 2129-2144. 
Gomi, K., V. Arbelaez, R. G. Crystal and M. S. Walters (2015). "Activation of NOTCH1 or 
NOTCH3 signaling skews human airway basal cell differentiation toward a secretory 
pathway." PLoS One 10(2): e0116507. 
Goodman, A. (2015). "HPV testing as a screen for cervical cancer." BMJ 350: h2372. 
Goodrich, J. A. and R. Tjian (2010). "Unexpected roles for core promoter recognition factors 
in cell-type-specific transcription and gene regulation." Nat Rev Genet 11(8): 549-558. 
Green, M. R. (2000). "TBP-associated factors (TAFIIs): multiple, selective transcriptional 
mediators in common complexes." Trends Biochem Sci 25(2): 59-63. 
Gridley, T. (2007). "Notch signaling in vascular development and physiology." Development 
134(15): 2709-2718. 
Groot, A. J., R. Habets, S. Yahyanejad, C. M. Hodin, K. Reiss, P. Saftig, J. Theys and M. 
Vooijs (2014). "Regulated proteolysis of NOTCH2 and NOTCH3 receptors by ADAM10 
and presenilins." Mol Cell Biol 34(15): 2822-2832. 
Groth, C. and M. E. Fortini (2012). "Therapeutic approaches to modulating Notch signaling: 
current challenges and future prospects." Semin Cell Dev Biol 23(4): 465-472. 
Grunberg, S. and S. Hahn (2013). "Structural insights into transcription initiation by RNA 
polymerase II." Trends Biochem Sci 38(12): 603-611. 
Guan, P., R. Howell-Jones, N. Li, L. Bruni, S. de Sanjose, S. Franceschi and G. M. Clifford 
(2012). "Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis 
from cervical infection to cancer." Int J Cancer 131(10): 2349-2359. 
Gustafsson, A. B. and R. A. Gottlieb (2008). "Heart mitochondria: gates of life and death." 
Cardiovasc Res 77(2): 334-343. 
Hahn, S. (2004). "Structure and mechanism of the RNA polymerase II transcription 
machinery." Nat Struct Mol Biol 11(5): 394-403. 
Hernandez Tejada, F. N., J. R. Galvez Silva and P. A. Zweidler-McKay (2014). "The 
challenge of targeting notch in hematologic malignancies." Front Pediatr 2: 54. 
Hicks, C., S. H. Johnston, G. diSibio, A. Collazo, T. F. Vogt and G. Weinmaster (2000). 
"Fringe differentially modulates Jagged1 and Delta1 signalling through Notch1 and Notch2." 
Nat Cell Biol 2(8): 515-520. 
Hoffmann, A., C. M. Chiang, T. Oelgeschlager, X. Xie, S. K. Burley, Y. Nakatani and R. G. 
Roeder (1996). "A histone octamer-like structure within TFIID." Nature 380(6572): 356-359. 
 
 
88 
88 
Hoiby, T., H. Zhou, D. J. Mitsiou and H. G. Stunnenberg (2007). "A facelift for the general 
transcription factor TFIIA." Biochim Biophys Acta 1769(7-8): 429-436. 
Hongmei, Z. (2012). "Extrinsic and Intrinsic Apoptosis Signal Pathway Review ". 
Iso, T., L. Kedes and Y. Hamamori (2003). "HES and HERP families: multiple effectors of 
the Notch signaling pathway." J Cell Physiol 194(3): 237-255. 
Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward and D. Forman (2011). "Global cancer 
statistics." CA Cancer J Clin 61(2): 69-90. 
Jennings, B. H. and D. Ish-Horowicz (2008). "The Groucho/TLE/Grg family of 
transcriptional co-repressors." Genome Biol 9(1): 205. 
Jiao, J., Z. Qin, S. Li, H. Liu and Z. Lu (2009). "Potential role of Notch1 signaling pathway 
in laryngeal squamous cell carcinoma cell line Hep-2 involving proliferation inhibition, cell 
cycle arrest, cell apoptosis, and cell migration." Oncol Rep 22(4): 815-823. 
Jonkers, I. and J. T. Lis (2015). "Getting up to speed with transcription elongation by RNA 
polymerase II." Nat Rev Mol Cell Biol 16(3): 167-177. 
Jonusiene, V., A. Sasnauskiene, N. Lachej, D. Kanopiene, D. Dabkeviciene, S. Sasnauskiene, 
B. Kazbariene and J. Didziapetriene (2013). "Down-regulated expression of Notch signaling 
molecules in human endometrial cancer." Med Oncol 30(1): 438. 
Jurisch-Yaksi, N., R. Sannerud and W. Annaert (2013). "A fast growing spectrum of 
biological functions of gamma-secretase in development and disease." Biochim Biophys 
Acta 1828(12): 2815-2827. 
Juven-Gershon, T. and J. T. Kadonaga (2010). "Regulation of gene expression via the core 
promoter and the basal transcriptional machinery." Dev Biol 339(2): 225-229. 
Kamtchueng, C., M. E. Stebenne, A. Delannoy, E. Wilhelm, H. Leger, A. G. Benecke and B. 
Bell (2014). "Alternative splicing of TAF6: downstream transcriptome impacts and upstream 
RNA splice control elements." PloS one 9(7): e102399. 
Kandiah, E., S. Trowitzsch, K. Gupta, M. Haffke and I. Berger (2014). "More pieces to the 
puzzle: recent structural insights into class II transcription initiation." Curr Opin Struct Biol 
24: 91-97. 
Kannan, S., W. Fang, G. Song, C. G. Mullighan, R. Hammitt, J. McMurray and P. A. 
Zweidler-McKay (2011). "Notch/HES1-mediated PARP1 activation: a cell type-specific 
mechanism for tumor suppression." Blood 117(10): 2891-2900. 
Kato, Y. (2011). "The multiple roles of Notch signaling during left-right patterning." Cell 
Mol Life Sci 68(15): 2555-2567. 
 
 
89 
89 
Kerr, J. F., A. H. Wyllie and A. R. Currie (1972). "Apoptosis: a basic biological phenomenon 
with wide-ranging implications in tissue kinetics." Br J Cancer 26(4): 239-257. 
Khan, M. J., P. E. Castle, A. T. Lorincz, S. Wacholder, M. Sherman, D. R. Scott, B. B. Rush, 
A. G. Glass and M. Schiffman (2005). "The elevated 10-year risk of cervical precancer and 
cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of 
type-specific HPV testing in clinical practice." J Natl Cancer Inst 97(14): 1072-1079. 
Kiechle, F. L. and X. Zhang (2002). "Apoptosis: biochemical aspects and clinical 
implications." Clin Chim Acta 326(1-2): 27-45. 
Kole, R., T. Williams and L. Cohen (2004). "RNA modulation, repair and remodeling by 
splice switching oligonucleotides." Acta Biochim Pol 51(2): 373-378. 
Konishi, J., F. Yi, X. Chen, H. Vo, D. P. Carbone and T. P. Dang (2010). "Notch3 cooperates 
with the EGFR pathway to modulate apoptosis through the induction of bim." Oncogene 
29(4): 589-596. 
Kopan, R. and M. X. G. Ilagan (2009). "The canonical Notch signaling pathway: unfolding 
the activation mechanism." Cell 137(2): 216-233. 
Kovall, R. A. (2008). "More complicated than it looks: assembly of Notch pathway 
transcription complexes." Oncogene 27(38): 5099-5109. 
Kume, T. (2009). "Novel insights into the differential functions of Notch ligands in vascular 
formation." J Angiogenes Res 1: 8. 
Lago, C., E. Clerici, L. Dreni, C. Horlow, E. Caporali, L. Colombo and M. M. Kater (2005). 
"The Arabidopsis TFIID factor AtTAF6 controls pollen tube growth." Dev Biol 285(1): 91-
100. 
Lai, E. C. (2002). "Keeping a good pathway down: transcriptional repression of Notch 
pathway target genes by CSL proteins." EMBO Rep 3(9): 840-845. 
Lathion, S., J. Schaper, P. Beard and K. Raj (2003). "Notch1 can contribute to viral-induced 
transformation of primary human keratinocytes." Cancer research 63(24): 8687-8694. 
Lavigne, A. C., Y. G. Gangloff, L. Carre, G. Mengus, C. Birck, O. Poch, C. Romier, D. 
Moras and I. Davidson (1999). "Synergistic transcriptional activation by TATA-binding 
protein and hTAFII28 requires specific amino acids of the hTAFII28 histone fold." Mol Cell 
Biol 19(7): 5050-5060. 
Lee, J. H., J. Suk, J. Park, S. B. Kim, S. S. Kwak, J. W. Kim, C. H. Lee, B. Byun, J. K. Ahn 
and C. O. Joe (2009). "Notch signal activates hypoxia pathway through HES1-dependent 
SRC/signal transducers and activators of transcription 3 pathway." Mol Cancer Res 7(10): 
1663-1671. 
 
 
90 
90 
Li, L., F. Zhao, J. Lu, T. Li, H. Yang, C. Wu and Y. Liu (2014). "Notch-1 Signaling Promotes 
the Malignant Features of Human Breast Cancer through NF-kappaB Activation." PloS one 
9(4): e95912. 
Liu, H., S. Kennard and B. Lilly (2009). "NOTCH3 expression is induced in mural cells 
through an autoregulatory loop that requires endothelial-expressed JAGGED1." Circ Res 
104(4): 466-475. 
Liu, X., D. A. Bushnell, D. A. Silva, X. Huang and R. D. Kornberg (2011). "Initiation 
complex structure and promoter proofreading." Science 333(6042): 633-637. 
Liu, Z. H., X. M. Dai and B. Du (2015). "Hes1: a key role in stemness, metastasis and 
multidrug resistance." Cancer Biol Ther 16(3): 353-359. 
Liu, Z. J., T. Shirakawa, Y. Li, A. Soma, M. Oka, G. P. Dotto, R. M. Fairman, O. C. 
Velazquez and M. Herlyn (2003). "Regulation of Notch1 and Dll4 by vascular endothelial 
growth factor in arterial endothelial cells: implications for modulating arteriogenesis and 
angiogenesis." Mol Cell Biol 23(1): 14-25. 
Lockshin, R. A. and J. Beaulaton (1974). "Programmed cell death." Life Sci 15(9): 1549-
1565. 
Lopez, J., G. Ruiz, J. Organista-Nava, P. Gariglio and A. Garcia-Carranca (2012). "Human 
papillomavirus infections and cancer stem cells of tumors from the uterine cervix." Open 
Virol J 6: 232-240. 
Louder, R. K., Y. He, J. R. Lopez-Blanco, J. Fang, P. Chacon and E. Nogales (2016). 
"Structure of promoter-bound TFIID and model of human pre-initiation complex assembly." 
Nature 531(7596): 604-609. 
Maglennon, G. A. and J. Doorbar (2012). "The biology of papillomavirus latency." Open 
Virol J 6: 190-197. 
Maier, M. M. and M. Gessler (2000). "Comparative analysis of the human and mouse Hey1 
promoter: Hey genes are new Notch target genes." Biochem Biophys Res Commun 275(2): 
652-660. 
Maliekal, T. T., J. Bajaj, V. Giri, D. Subramanyam and S. Krishna (2008). "The role of Notch 
signaling in human cervical cancer: implications for solid tumors." Oncogene 27(38): 5110-
5114. 
Malkowska, M., K. Kokoszynska, L. Rychlewski and L. Wyrwicz (2013). "Structural 
bioinformatics of the general transcription factor TFIID." Biochimie 95(4): 680-691. 
Matsuda, M., M. Koga, E. Nishida and M. Ebisuya (2012). "Synthetic signal propagation 
through direct cell-cell interaction." Sci Signal 5(220): ra31. 
 
 
91 
91 
Melino, G., E. Gallagher, R. I. Aqeilan, R. Knight, A. Peschiaroli, M. Rossi, F. Scialpi, M. 
Malatesta, L. Zocchi, G. Browne, A. Ciechanover and F. Bernassola (2008). "Itch: a HECT-
type E3 ligase regulating immunity, skin and cancer." Cell Death Differ 15(7): 1103-1112. 
Michel, B., P. Komarnitsky and S. Buratowski (1998). "Histone-like TAFs are essential for 
transcription in vivo." Mol Cell 2(5): 663-673. 
Monahan, P., S. Rybak and L. T. Raetzman (2009). "The notch target gene HES1 regulates 
cell cycle inhibitor expression in the developing pituitary." Endocrinology 150(9): 4386-
4394. 
Moody, C. A. and L. A. Laimins (2010). "Human papillomavirus oncoproteins: pathways to 
transformation." Nature Reviews. Cancer 10(8): 550-560. 
Morgan, T. H. (1917). "The Theory of the gene." The American Naturalist 51: 513-544. 
Münger, K., J. R. Basile, S. Duensing, A. Eichten, S. L. Gonzalez, M. Grace and V. L. Zacny 
(2001). "Biological activities and molecular targets of the human papillomavirus E7 
oncoprotein." Oncogene 20(54): 7888-7898. 
Neradil, J., G. Pavlasova, M. Sramek, M. Kyr, R. Veselska and J. Sterba (2015). "DHFR-
mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: the same 
outcome of treatment with different doses in sensitive cell lines." Oncol Rep 33(5): 2169-
2175. 
Nickoloff, B. J., M. J. Hendrix, P. M. Pollock, J. M. Trent, L. Miele and J. Z. Qin (2005). 
"Notch and NOXA-related pathways in melanoma cells." J Investig Dermatol Symp Proc 
10(2): 95-104. 
Nicolas, M., A. Wolfer, K. Raj, J. A. Kummer, P. Mill, M. van Noort, C. C. Hui, H. Clevers, 
G. P. Dotto and F. Radtke (2003). "Notch1 functions as a tumor suppressor in mouse skin." 
Nat Genet 33(3): 416-421. 
Noth, S. and A. Benecke (2005). "Avoiding inconsistencies over time and tracking 
difficulties in Applied Biosystems AB1700/Panther probe-to-gene annotations." BMC 
Bioinformatics 6: 307. 
Noth, S., G. Brysbaert and A. Benecke (2006). "Normalization using weighted negative 
second order exponential error functions (NeONORM) provides robustness against 
asymmetries in comparative transcriptome profiles and avoids false calls." Genomics 
Proteomics Bioinformatics 4(2): 90-109. 
Nowell, C. S. and F. Radtke (2017). "Notch as a tumour suppressor." Nat Rev Cancer 17(3): 
145-159. 
Ntziachristos, P., J. S. Lim, J. Sage and I. Aifantis (2014). "From fly wings to targeted cancer 
therapies: a centennial for notch signaling." Cancer Cell 25(3): 318-334. 
 
 
92 
92 
Okochi, M., H. Steiner, A. Fukumori, H. Tanii, T. Tomita, T. Tanaka, T. Iwatsubo, T. Kudo, 
M. Takeda and C. Haass (2002). "Presenilins mediate a dual intramembranous gamma-
secretase cleavage of Notch-1." EMBO J 21(20): 5408-5416. 
Olsauskas-Kuprys, R., A. Zlobin and C. Osipo (2013). "Gamma secretase inhibitors of Notch 
signaling." Onco Targets Ther 6: 943-955. 
Ouyang, L., Z. Shi, S. Zhao, F. T. Wang, T. T. Zhou, B. Liu and J. K. Bao (2012). 
"Programmed cell death pathways in cancer: a review of apoptosis, autophagy and 
programmed necrosis." Cell Prolif 45(6): 487-498. 
Pancewicz, J. and C. Nicot (2011). "Current views on the role of Notch signaling and the 
pathogenesis of human leukemia." BMC Cancer 11: 502. 
Papai, G., P. A. Weil and P. Schultz (2011). "New insights into the function of transcription 
factor TFIID from recent structural studies." Curr Opin Genet Dev 21(2): 219-224. 
Parrish, A. B., C. D. Freel and S. Kornbluth (2013). "Cellular mechanisms controlling 
caspase activation and function." Cold Spring Harb Perspect Biol 5(6). 
Ploner, C., R. Kofler and A. Villunger (2008). "Noxa: at the tip of the balance between life 
and death." Oncogene 27 Suppl 1: S84-92. 
Porrua, O., M. Boudvillain and D. Libri (2016). "Transcription Termination: Variations on 
Common Themes." Trends Genet 32(8): 508-522. 
Prabhu, S. B., J. K. Khalsa, H. Banerjee, A. Das, S. Srivastava, H. R. Mattoo, K. Thyagarajan, 
S. Tanwar, D. S. Das, S. S. Majumdar, A. George, V. Bal, J. M. Durdik and S. Rath (2013). 
"Role of apoptosis-inducing factor (Aif) in the T cell lineage." Indian J Med Res 138(5): 577-
590. 
Previs, R. A., R. L. Coleman, A. L. Harris and A. K. Sood (2015). "Molecular pathways: 
translational and therapeutic implications of the Notch signaling pathway in cancer." Clin 
Cancer Res 21(5): 955-961. 
Radtke, F. and K. Raj (2003). "The role of Notch in tumorigenesis: oncogene or tumour 
suppressor?" Nature Reviews. Cancer 3(10): 756-767. 
Rajesh P. Rastogi, R. a. R. P. S. (2009). "Apoptosis: Molecular Mechanisms and 
Pathogenicity " EXCLI Journal 8: 155-181. 
Rand, M. D., L. M. Grimm, S. Artavanis-Tsakonas, V. Patriub, S. C. Blacklow, J. Sklar and 
J. C. Aster (2000). "Calcium depletion dissociates and activates heterodimeric notch 
receptors." Mol Cell Biol 20(5): 1825-1835. 
Ranganathan, P., K. L. Weaver and A. J. Capobianco (2011). "Notch signalling in solid 
tumours: a little bit of everything but not all the time." Nat Rev Cancer 11(5): 338-351. 
 
 
93 
93 
Rangarajan, A., R. Syal, S. Selvarajah, O. Chakrabarti, A. Sarin and S. Krishna (2001). 
"Activated Notch1 signaling cooperates with papillomavirus oncogenes in transformation 
and generates resistance to apoptosis on matrix withdrawal through PKB/Akt." Virology 
286(1): 23-30. 
Rathmell, J. C. and C. B. Thompson (2002). "Pathways of apoptosis in lymphocyte 
development, homeostasis, and disease." Cell 109 Suppl: S97-107. 
Reed, J. C. (2002). "Apoptosis-based therapies." Nat Rev Drug Discov 1(2): 111-121. 
Reese, J. C. (2003). "Basal transcription factors." Curr Opin Genet Dev 13(2): 114-118. 
Reid, R. (1983). "Genital warts and cervical cancer. II. Is human papillomavirus infection 
the trigger to cervical carcinogenesis?" Gynecologic oncology 15(2): 239-252. 
Riedl, S. J. and Y. Shi (2004). "Molecular mechanisms of caspase regulation during 
apoptosis." Nat Rev Mol Cell Biol 5(11): 897-907. 
Robert-Moreno, A., L. Espinosa, J. L. de la Pompa and A. Bigas (2005). "RBPjkappa-
dependent Notch function regulates Gata2 and is essential for the formation of intra-
embryonic hematopoietic cells." Development 132(5): 1117-1126. 
Robert-Moreno, A., L. Espinosa, M. J. Sanchez, J. L. de la Pompa and A. Bigas (2007). "The 
notch pathway positively regulates programmed cell death during erythroid differentiation." 
Leukemia 21(7): 1496-1503. 
Rode, H.-J. (2005). "Apoptosis, Cell Death, and Cell Proliferation." 2-5. 
Sakamoto, K., T. Fujii, H. Kawachi, Y. Miki, K. Omura, K.-i. Morita, K. Kayamori, K.-i. 
Katsube and A. Yamaguchi (2012). "Reduction of NOTCH1 expression pertains to 
maturation abnormalities of keratinocytes in squamous neoplasms." Laboratory 
investigation; a journal of technical methods and pathology 92(5): 688-702. 
Saraste, A. and K. Pulkki (2000). "Morphologic and biochemical hallmarks of apoptosis." 
Cardiovasc Res 45(3): 528-537. 
Saravanamuthu, S. S., C. Y. Gao and P. S. Zelenka (2009). "Notch signaling is required for 
lateral induction of Jagged1 during FGF-induced lens fiber differentiation." Dev Biol 332(1): 
166-176. 
Scheer, E., F. Delbac, L. Tora, D. Moras and C. Romier (2012). "TFIID TAF6-TAF9 
complex formation involves the HEAT repeat-containing C-terminal domain of TAF6 and is 
modulated by TAF5 protein." J Biol Chem 287(33): 27580-27592. 
Scheffner, M., B. A. Werness, J. M. Huibregtse, A. J. Levine and P. M. Howley (1990). "The 
E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation 
of p53." Cell 63(6): 1129-1136. 
 
 
94 
94 
Schroeter, E. H., J. A. Kisslinger and R. Kopan (1998). "Notch-1 signalling requires ligand-
induced proteolytic release of intracellular domain." Nature 393(6683): 382-386. 
Schwanbeck, R., S. Martini, K. Bernoth and U. Just (2011). "The Notch signaling pathway: 
molecular basis of cell context dependency." European journal of cell biology 90(6-7): 572-
581. 
Selleck, W., R. Howley, Q. Fang, V. Podolny, M. G. Fried, S. Buratowski and S. Tan (2001). 
"A histone fold TAF octamer within the yeast TFIID transcriptional coactivator." Nat Struct 
Biol 8(8): 695-700. 
Shandilya, J. and S. G. Roberts (2012). "The transcription cycle in eukaryotes: from 
productive initiation to RNA polymerase II recycling." Biochim Biophys Acta 1819(5): 391-
400. 
Shao, H., M. Revach, S. Moshonov, Y. Tzuman, K. Gazit, S. Albeck, T. Unger and R. 
Dikstein (2005). "Core promoter binding by histone-like TAF complexes." Mol Cell Biol 
25(1): 206-219. 
Shimizu, K., S. Chiba, N. Hosoya, K. Kumano, T. Saito, M. Kurokawa, Y. Kanda, Y. 
Hamada and H. Hirai (2000). "Binding of Delta1, Jagged1, and Jagged2 to Notch2 rapidly 
induces cleavage, nuclear translocation, and hyperphosphorylation of Notch2." Mol Cell Biol 
20(18): 6913-6922. 
Sikorski, T. W. and S. Buratowski (2009). "The basal initiation machinery: beyond the 
general transcription factors." Curr Opin Cell Biol 21(3): 344-351. 
Sionov, R. V., S. A. Vlahopoulos and Z. Granot (2015). "Regulation of Bim in Health and 
Disease." Oncotarget 6(27): 23058-23134. 
Smith, J. S., L. Lindsay, B. Hoots, J. Keys, S. Franceschi, R. Winer and G. M. Clifford 
(2007). "Human papillomavirus type distribution in invasive cervical cancer and high-grade 
cervical lesions: a meta-analysis update." Int J Cancer 121(3): 621-632. 
Sriuranpong, V., M. W. Borges, R. K. Ravi, D. R. Arnold, B. D. Nelkin, S. B. Baylin and D. 
W. Ball (2001). "Notch signaling induces cell cycle arrest in small cell lung cancer cells." 
Cancer Res 61(7): 3200-3205. 
Steenbergen, R. D., P. J. Snijders, D. A. Heideman and C. J. Meijer (2014). "Clinical 
implications of (epi)genetic changes in HPV-induced cervical precancerous lesions." Nat 
Rev Cancer 14(6): 395-405. 
Tait, S. W. and D. R. Green (2010). "Mitochondria and cell death: outer membrane 
permeabilization and beyond." Nat Rev Mol Cell Biol 11(9): 621-632. 
Takam Kamga, P., G. Bassi, A. Cassaro, M. Midolo, M. Di Trapani, A. Gatti, R. Carusone, 
F. Resci, O. Perbellini, M. Gottardi, M. Bonifacio, A. H. Nwabo Kamdje, A. Ambrosetti and 
 
 
95 
95 
M. Krampera (2016). "Notch signalling drives bone marrow stromal cell-mediated 
chemoresistance in acute myeloid leukemia." Oncotarget 7(16): 21713-21727. 
Talora, C., S. Cialfi, O. Segatto, S. Morrone, J. Kim Choi, L. Frati, G. Paolo Dotto, A. Gulino 
and I. Screpanti (2005). "Constitutively active Notch1 induces growth arrest of HPV-positive 
cervical cancer cells via separate signaling pathways." Experimental Cell Research 305(2): 
343-354 %U http://www.sciencedirect.com/science/article/pii/S001448270500042X. 
Talora, C., D. C. Sgroi, C. P. Crum and G. P. Dotto (2002). "Specific down-modulation of 
Notch1 signaling in cervical cancer cells is required for sustained HPV-E6/E7 expression 
and late steps of malignant transformation." Genes & Development 16(17): 2252-2263. 
Tchitchek, N., J. F. Dzib, B. Targat, S. Noth, A. Benecke and A. Lesne (2012). "CDS: a fold-
change based statistical test for concomitant identification of distinctness and similarity in 
gene expression analysis." Genomics Proteomics Bioinformatics 10(3): 127-135. 
Thomas, M. C. and C. M. Chiang (2006). "The general transcription machinery and general 
cofactors." Crit Rev Biochem Mol Biol 41(3): 105-178. 
Thuault, S., Y. G. Gangloff, J. Kirchner, S. Sanders, S. Werten, C. Romier, P. A. Weil and I. 
Davidson (2002). "Functional analysis of the TFIID-specific yeast TAF4 (yTAF(II)48) 
reveals an unexpected organization of its histone-fold domain." J Biol Chem 277(47): 45510-
45517. 
Tolia, A. and B. De Strooper (2009). "Structure and function of gamma-secretase." Semin 
Cell Dev Biol 20(2): 211-218. 
Van Cruchten, S. and W. Van Den Broeck (2002). "Morphological and biochemical aspects 
of apoptosis, oncosis and necrosis." Anat Histol Embryol 31(4): 214-223. 
Vande Walle, L., M. Lamkanfi and P. Vandenabeele (2008). "The mitochondrial serine 
protease HtrA2/Omi: an overview." Cell Death Differ 15(3): 453-460. 
Wang, L., H. Qin, B. Chen, X. Xin, J. Li and H. Han (2007). "Overexpressed active Notch1 
induces cell growth arrest of HeLa cervical carcinoma cells." International journal of 
gynecological cancer: official journal of the International Gynecological Cancer Society 
17(6): 1283-1292. 
Wang, M., L. Wu, L. Wang and X. Xin (2010). "Down-regulation of Notch1 by gamma-
secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells 
A2780." Biochem Biophys Res Commun 393(1): 144-149. 
Wang, M. M. (2011). "Notch signaling and Notch signaling modifiers." Int J Biochem Cell 
Biol 43(11): 1550-1562. 
Wang, W., Y. Jossin, G. Chai, W. H. Lien, F. Tissir and A. M. Goffinet (2016). "Feedback 
regulation of apical progenitor fate by immature neurons through Wnt7-Celsr3-Fzd3 
signalling." Nat Commun 7: 10936. 
 
 
96 
96 
Wang, W., R. Nahta, G. Huper and J. R. Marks (2004). "TAFII70 isoform-specific growth 
suppression correlates with its ability to complex with the GADD45a protein." Mol Cancer 
Res 2(8): 442-452. 
Wang, Z., Y. Li, S. Banerjee, D. Kong, A. Ahmad, V. Nogueira, N. Hay and F. H. Sarkar 
(2010). "Down-regulation of Notch-1 and Jagged-1 inhibits prostate cancer cell growth, 
migration and invasion, and induces apoptosis via inactivation of Akt, mTOR, and NF-
kappaB signaling pathways." J Cell Biochem 109(4): 726-736. 
Weijzen, S., A. Zlobin, M. Braid, L. Miele and W. M. Kast (2003). "HPV16 E6 and E7 
oncoproteins regulate Notch-1 expression and cooperate to induce transformation." Journal 
of cellular physiology 194(3): 356-362. 
Weinzierl, R. O., S. Ruppert, B. D. Dynlacht, N. Tanese and R. Tjian (1993). "Cloning and 
expression of Drosophila TAFII60 and human TAFII70 reveal conserved interactions with 
other subunits of TFIID." EMBO J 12(13): 5303-5309. 
Werten, S., A. Mitschler, C. Romier, Y. G. Gangloff, S. Thuault, I. Davidson and D. Moras 
(2002). "Crystal structure of a subcomplex of human transcription factor TFIID formed by 
TATA binding protein-associated factors hTAF4 (hTAF(II)135) and hTAF12 
(hTAF(II)20)." J Biol Chem 277(47): 45502-45509. 
Wharton, K. A., K. M. Johansen, T. Xu and S. Artavanis-Tsakonas (1985). "Nucleotide 
sequence from the neurogenic locus notch implies a gene product that shares homology with 
proteins containing EGF-like repeats." Cell 43(3 Pt 2): 567-581. 
Wilhelm, E., M. Kornete, B. Targat, J. Vigneault-Edwards, M. Frontini, L. Tora, A. Benecke 
and B. Bell (2010). "TAF6delta orchestrates an apoptotic transcriptome profile and interacts 
functionally with p53." BMC molecular biology 11: 10. 
Wilhelm, E., F.-X. Pellay, A. Benecke and B. Bell (2008). "TAF6delta controls apoptosis 
and gene expression in the absence of p53." PloS one 3(7): e2721. 
Yang, S., Y. Liu, B. Xia, J. Deng, T. Liu, Q. Li, Y. Yang, Y. Wang, X. Ning, Y. Zhang and 
M. Xiao (2016). "DLL4 as a predictor of pelvic lymph node metastasis and a novel prognostic 
biomarker in patients with early-stage cervical cancer." Tumour Biol 37(4): 5063-5074. 
Yang, X., R. Klein, X. Tian, H. T. Cheng, R. Kopan and J. Shen (2004). "Notch activation 
induces apoptosis in neural progenitor cells through a p53-dependent pathway." Dev Biol 
269(1): 81-94. 
Yao, J., L. Duan, M. Fan, J. Yuan and X. Wu (2007). "Notch1 induces cell cycle arrest and 
apoptosis in human cervical cancer cells: involvement of nuclear factor kappa B inhibition." 
International journal of gynecological cancer: official journal of the International 
Gynecological Cancer Society 17(2): 502-510. 
Yin, L., O. C. Velazquez and Z. J. Liu (2010). "Notch signaling: emerging molecular targets 
for cancer therapy." Biochem Pharmacol 80(5): 690-701. 
 
 
97 
97 
Zagouras, P., S. Stifani, C. M. Blaumueller, M. L. Carcangiu and S. Artavanis-Tsakonas 
(1995). "Alterations in Notch signaling in neoplastic lesions of the human cervix." 
Proceedings of the National Academy of Sciences of the United States of America 92(14): 
6414-6418. 
Zhang, L. N., J. Y. Li and W. Xu (2013). "A review of the role of Puma, Noxa and Bim in 
the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia." Cancer 
Gene Ther 20(1): 1-7. 
Zhang, S., W. C. Chung, G. Wu, S. E. Egan and K. Xu (2014). "Tumor-suppressive activity 
of Lunatic Fringe in prostate through differential modulation of Notch receptor activation." 
Neoplasia 16(2): 158-167. 
Zhang, Y. and B. Herman (2002). "Ageing and apoptosis." Mech Ageing Dev 123(4): 245-
260. 
Zhou, S., M. Fujimuro, J. J. Hsieh, L. Chen, A. Miyamoto, G. Weinmaster and S. D. Hayward 
(2000). "SKIP, a CBF1-associated protein, interacts with the ankyrin repeat domain of 
NotchIC To facilitate NotchIC function." Mol Cell Biol 20(7): 2400-2410. 
Zimmermann, K. C., C. Bonzon and D. R. Green (2001). "The machinery of programmed 
cell death." Pharmacol Ther 92(1): 57-70. 
zur Hausen, H. (1996). "Papillomavirus infections--a major cause of human cancers." 
Biochimica et biophysica acta 1288(2): F55-78. 
zur Hausen, H. (2002). "Papillomaviruses and cancer: from basic studies to clinical 
application." Nature Reviews. Cancer 2(5): 342-350. 
Zweidler-McKay, P. A., Y. He, L. Xu, C. G. Rodriguez, F. G. Karnell, A. C. Carpenter, J. C. 
Aster, D. Allman and W. S. Pear (2005). "Notch signaling is a potent inducer of growth arrest 
and apoptosis in a wide range of B-cell malignancies." Blood 106(12): 3898-3906. 
 
 
 
